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ABSTRACT 
 
PROLIFERATION AND SURVIVAL MECHANISMS IN SOFT TISSUE 
SARCOMA AND GLIOBLASTOMA TUMORS. 
Vera Mucaj 
M. Celeste Simon 
 Soft tissue sarcomas and glioblastomas are two deadly tumors that are characterized by 
aggressive overproliferation, and regions of severe intratumoral nutrient and oxygen deprivation. 
The mechanisms by which tumors evade proliferation control signals and survive in a hostile 
microenvironment are active areas of investigation. This work describes two projects investigating 
loss of proliferation control in soft tissue sarcoma, as a result of Hippo pathway deregulation, and 
mechanisms of survival under stress in glioblastoma, as a result of decreased microRNA-124 
(miR-124) levels. First, we demonstrate that the Hippo pathway is deregulated in soft tissue 
sarcoma patient samples, leading to overexpression of the Hippo effector YAP. YAP, a 
transcriptional coactivator, binds to TEAD proteins in the nucleus and controls the transcription of 
multiple pro-proliferation and anti-apoptosis targets, including the transcription factor FOXM1. 
Interestingly, we show that FOXM1 physically interacts with the TEAD/YAP complex, creating a 
powerful pro-proliferation complex. FOXM1 genetic deletion and pharmacologic inhibition resulted 
in decreased sarcoma tumor size, suggesting that FOXM1 inhibition is a viable potential sarcoma 
treatment. Second, we show that ectopically expressing miR-124 in glioblastoma cells leads to 
increased cell death. We identify three factors (SERP1, TEAD1, and MAPK14) as direct miR-124 
targets and partial effectors of cell survival under stress. Inhibition of these targets recapitulates 
the miR-124 cell death phenotype under stress, and decreased glioma growth in vivo. 
Importantly, miR-124 ectopic expression results in increased survival in an in vivo orthotopic 
intracranial glioma model, suggesting that expression of miR-124, or inhibition of its downstream 
targets, is an attractive way of targeting glioblastoma cells residing in hypoxic/ischemic regions, 
and ultimately a method of investigating novel glioblastoma treatments. 
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CHAPTER 1  
Growth control and survival in soft tissue sarcoma and glioblastoma.  
 
INTRODUCTION 
Proliferation and cell survival are two key processes required for all living cells. 
Appropriate control of the mechanisms governing proliferation and survival is necessary for 
proper cellular and organismic homeostasis. Malignant tumors are characterized by their ability to 
overcome restrictions on growth and proliferation and by their ability to survive the 
microenvironment arising as a result of abnormal proliferation. These properties have been 
extensively reviewed in the cancer biology literature, and are tightly connected to the “hallmarks” 
of cancer characterized by Hanahan and Weinberg, which generally define our current 
understanding of tumor initiation and progression. (Hanahan and Weinberg, 2000, 2011).  
How tumor cells evade signals that restrict proliferation and how they survive under 
stress are two important phenomena in the field of cancer research. These are complex 
phenotypes, resulting in part due to universal mechanisms co-opted by cancer cells. However, 
some mechanisms are specific to a subset of cancers, depending on the oncogenic and tumor 
suppressive networks aberrantly regulated in a particular tumor. Of particular interest are the 
mechanisms that govern proliferation and survival in the highly aggressive mesenchymal 
glioblastoma multiforme and soft tissue sarcoma tumors. While these tumors have disparate 
etiologies and treatment modalities, they also possess some remarkably similar tissue 
architecture and molecular signatures. Besides the common expression of genes associated with 
mesenchymal tissues, both glioblastomas and soft tissue sarcomas (i.e. Undifferentiated 
Pleomorphic Sarcoma (UPS)) are characterized by high rates of proliferation, and perhaps 
subsequent to hyperproliferation, the presence of a very hypoxic/ischemic microenvironment 
(Eisinger-Mathason et al., 2013; Mathew et al., 2014b; Mucaj et al., 2014). This body of work 
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aims to answer the following two questions (1) which pathways drive proliferation and (2) how is 
survival under an aggressive microenvironment achieved in mesenchymal tumors?  
One important pathway involved in proliferation control is the Hippo pathway. In this 
chapter, I will introduce background information on the Hippo pathway and its roles in regulating 
cell proliferation and tissue size determination (Part I). Additionally, I will outline how microRNA 
expression changes can modulate cellular survival, especially under nutrient, growth factor and 
oxygen deprivation (Part II). As the work comprising this dissertation has been conducted in the 
soft tissue sarcoma and glioblastoma models, two types of tumors expressing a mesenchymal 
signature, background information on sarcoma/glioblastoma will follow in Chapters II and III, 
where I describe how the Hippo pathway is deregulated in soft tissue sarcoma, and how 
microRNA-124 loss leads to glioblastoma survival under nutrient and oxygen deprivation (Mucaj 
et al., 2014). 
PART I. THE HIPPO PATHWAY AND PROLIFERATION CONTROL 
A. Hippo Pathway Overview 
Tissue size control is an intriguing developmental biology puzzle. Through tight control of 
proliferation signals, the Hippo pathway is currently thought to be a key regulator of tissue and 
organ size (Mo et al., 2014; Pan, 2010). Originally delineated in the Drosophila Melanogaster 
model, the Hippo pathway is evolutionarily conserved from premetazoan ameboid species to 
mammalians (Sebe-Pedros et al., 2012). The role of the Hippo pathway has been studied 
extensively in the past two decades, starting from the original discovery of the Yes Associated 
Protein (YAP) in a screen for proteins binding to the Yes kinase (Sudol, 1994). It took more than a 
decade between YAP description and the discovery that the conserved Hippo pathway kinase 
cascade inhibited YAP, as well as YAP homolog Transcription coactivator with PDZ motif (TAZ), 
to blunt proliferation signaling within a cell (Dong et al., 2007; Varelas, 2014). 
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 In mammals, the pathway is thought to respond to contact inhibition or diffusible 
extracellular signals by activating the Mammalian sterile 20-like kinases 1 and 2 (MST1/MST2). 
While these upstream events are still incompletely understood and are an area of active 
investigation (Park and Guan, 2013), intracellular proteins including Neurofibromatosis II (NF2, 
also known as Merlin), Expanded (Ex) and Kidney and Brain Protein (KIBRA, also known as 
WWC1) have been shown to be crucial mediators linking the extracellular signals to YAP 
inhibition (Genevet et al., 2010; Hamaratoglu et al., 2006; Yu et al., 2010; Zhang et al., 2010). 
MST1/2 are dependent upon the Salvador homolog 1 (SAV1, also called WW45) adaptor for their 
kinase activity (Callus et al., 2006; Pan, 2010). In turn, the MST/SAV1 complex phosphorylates 
and activates the Large Tumor Suppressor kinases 1 and 2 (LATS1/2), which are bound by the 
MOB1 adaptor complex (Chan et al., 2005). The LATS complex phosphorylates YAP, leading to 
recognition and binding by 14-3-3 proteins, and resulting in YAP cytoplasmic sequestration or 
proteasomal degradation (Hao et al., 2008; Zhao et al., 2010b; Zhao et al., 2007). Upon pro-
proliferation signaling, the Hippo pathway is inactivated, allowing unphosphorylated YAP to 
translocate into the nucleus, where it binds the Tea Domain Family of transcription factors 
(TEAD1-4) and directs the transcription of multiple factors required for proliferation (Zhao et al., 
2008c) and survival (Dong et al., 2007). 
B. Hippo pathway members and regulation 
Many factors are implicated in the overarching Hippo signaling pathway. This section 
highlights the importance of many Hippo components in cellular homeostasis maintenance, and 
underscores the importance of an intact Hippo pathway in preventing deregulation that may result 
in tumorigenesis. Table 1 provides an overview of the players currently linked to the Hippo 
pathway. Below, I outline some key players involved in the Hippo core kinase complex, the 
upstream Hippo regulators, as well as the downstream nuclear effectors. These players are 
delineated in the schematic of the Hippo pathway in Fig. 1. 
The Hippo core kinase complex. 
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The Drosophila Hippo pathway is composed of a kinase cascade including the Hippo 
(Hpo) kinase and its adaptor Salvador, as well as the Drosophila LATS (dLATS) or Warts (Wts) 
kinase and its adaptor Mob as tumor suppressor (MATS or MOB1) (Pan, 2007). The drosophila 
kinases were discovered in screens for pro-proliferation factors. Hpo and Wts mutants led to 
hyperproliferation of the Drosphila imaginal disc (Harvey et al., 2003; Jia et al., 2003; Udan et al., 
2003; Wu et al., 2003). These studies and others demonstrated that Hpo and Wts controlled the 
function of Yorkie (Yki), a transcriptional coactivator whose loss leads to decreased tissue 
proliferation in drosophila (Huang et al., 2005). The Ser/Thre kinases MST1 and 2 were identified 
as the Hpo counterparts in mammals, whereas YAP was identified as the Yki ortholog, and 
MST1/2 – mediated phosphorylation of the mammalian Wts homologs Lats1 and 2 was found to 
be necessary for YAP cytoplasmic retention (Dong et al., 2007; Pan, 2007). 
Mst kinase activation is mediated through autophosphorylation (Praskova et al., 2004), 
but adaptor proteins are necessary for this activation to occur. Using biochemistry and molecular 
biology approaches, Callus and colleagues showed that human SAV1 binds to MST1/2 at the Mst 
C-terminal coiled-coiled domain and this association causes both MST and SAV1 
phosphorylation. The phosphorylated complex is considered activated, and SAV1 loss abrogates 
MST activation (Callus et al., 2006). In addition to autophosophorylation, the MST/SAV1 complex 
separately phosophorylates the MOB1 complex as well as the LATS kinases. Similarly to 
Mst/Sav1, human MOB1 has been shown to be necessary for LATS activation (Hergovich et al., 
2006). Further studies have suggested that Mst/Sav/Lats/Mob1 all bind as part of a complex 
which dynamically controls cell proliferation fate (Sudol and Harvey, 2010). 
While there have been instances where MST1/2-mediated LATS phosphorylation is not 
necessary for YAP inhibition, particularly in Mouse Embryonal Fibroblasts (MEFs) (Zhou et al., 
2009), the MST/SAV1-LATS/MOB signaling is considered the core of the Hippo pathway, and is 
the best understood signaling module within the pathway (Pan, 2010; Park and Guan, 2013; Yu 
and Guan, 2013) 
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Upstream regulators and intracellular mediators. 
To date, the full spectrum of events leading to Hippo pathway activation remains 
incompletely understood. In vitro, high cell density/confluency has been repeatedly shown to 
affect YAP phosphorylation and cytoplasmic retention, suggesting that cell contact inhibition 
activates the Hippo pathway (Dupont et al., 2011; Overholtzer et al., 2006; Zhao et al., 2007). It is 
possible that this phenotype is mediated through polarity/tight junction regulation and 
mechanotransduction.  
Drosophila genetic screens have provided some early insight into regulators upstream of 
the core kinase cassette, implicating key players involved in cell polarity (Yu and Guan, 2013).  
Several parallel studies identified the Fat (Ft) and Dachsous (Ds) tumor suppressors, two 
membrane proteins involved in the establishment of Planar Cell Polarity (PCP), as well as their 
downstream effectors, as YAP negative regulators (Bennett and Harvey, 2006; Feng and Irvine, 
2007; Silva et al., 2006). While the PCP is largely considered a property of epithelial cells, this 
network is also present in mesenchymal cells. In fact, the PCP is thought to be important during 
gastrulation and the formation of the mesenchyme (Mlodzik, 2002),  for cellular interchalation 
(Simons and Mlodzik, 2008), directed movement (Tada and Kai, 2012), neural crest migration 
(Clay and Halloran, 2011) and myogenesis (Gros et al., 2009). The current understanding is that 
Ft/Ds signaling affects the Hippo pathway through activating the core kinase cassette, either 
directly by activating Wts or through Dachs, an atypical myosin (Yu and Guan, 2013). The 
mammalian PCP complex is more complicated, with several Ft and Ds orthologs (Bossuyt et al., 
2014). Nonetheless, the upstream regulation of Hippo by PCP components seems to be 
conserved in mammalian cells.  
In addition to PCP, the apical-basal polarity complexes are also significant for Hippo 
pathway activity. Apical-basal polarity is determined by the localization of tight and adherens 
junctions (TJ, AJ) (McCaffrey and Macara, 2011). TJ and AJ complexes are important for 
maintaining epithelial tissue organization, and disruption of TJ and AJ is one of the key steps in 
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Epithelial-to-Mesenchymal transition, both in development and tumorigenesis (Lamouille et al., 
2014). Varelas and colleagues showed that perturbation of TJ or AJs leads to nuclear YAP 
localization (Varelas et al., 2010). This finding is supported by the fact that key components of TJ 
and AJ complexes have been associated with Hippo pathway activation. Three of these 
components are NF2/Merlin, Expanded (Ex) and Kibra.  
NF2, Ex and Kibra are intracellular mediators thought to localize at the apical side of the 
cell membrane of polarized epithelial cells (Genevet et al., 2010; Hamaratoglu et al., 2006; Yu 
and Guan, 2013). The localization of NF2/Ex/Kibra in mesenchymal cells is unclear, but the 
expression of at least NF2 has been described in mesenchymal tissues (den Bakker et al., 1995; 
McClatchey et al., 1998; Shaw et al., 1998). NF2, Ex and Kibra have been shown to control 
proliferation rates in normal cells (Baumgartner et al., 2010; Genevet et al., 2010; Ji et al., 2012; 
McCartney et al., 2000) and are considered to be tumor suppressors (Yi et al., 2011; Yu et al., 
2010; Zhang et al., 2010). 
Other players of TJ and AJ complexes have been associated with physical restriction of 
YAP into the cytoplasm. YAP has been shown to interact with Angiomotin proteins (AMOT, 
AMOTL1 and AMOTL2, which are considered AJ members) and possibly with Zona Occludens 
proteins (ZO1, ZO2, TJ members) as well as non-receptor tyrosine phosphatase 14 (PTPN14, 
also found at the TJ) (Wang et al., 2012; Yi et al., 2013; Zhao et al., 2011a). Initial studies 
identified AMOTs as negative regulators of YAP, which functioned by sequestering YAP to the 
AJ. However, the relationship between YAP and AMOT proteins is more nuanced, as a further 
study has demonstrated cooperation between YAP and AMOT as a transcriptional complex in the 
nucleus (Yi et al., 2013) 
As hinted by the in vitro observation that cell density affects YAP localization, mechanical 
cues are crucial to Hippo pathway function. Cells modify shape in response to stiffness changes 
caused by the extracellular matrix (ECM) as well as in response to contact with neighboring cells, 
and these changes get transduced into signaling via cytoskeleton alterations. Pointedly, contact 
7 
 
inhibition loss is a key property of cancer cells (Hanahan and Weinberg, 2011). Various studies 
have linked YAP and TAZ nuclear/cytoplasmic transolcation to mechanotransduction, whereby 
stiffer surfaces lead to more nuclear YAP and TAZ localization, and, vice versa, decreased 
stiffness causing YAP/TAZ cytoplasmic retention (Calvo et al., 2013; Dupont et al., 2011; Wada et 
al., 2011; Zhao et al., 2012). Interestingly, Dupont and colleagues showed that modulating 
stiffness in vitro is sufficient to cause mesenchymal stem cell (MSC) differentiation into 
adipogenic or osteogenic lineages in a YAP/TAZ dependent manner (Dupont et al., 2011).  
In addition to responding to mechanical cues, it has been hypothesized that the Hippo 
pathway could be modulated by diffusible signals (ie ligand-receptor interactions). Recently, G-
protein coupled receptor (GPCR) ligands have been identified as the first extracellular factors 
responsible for Hippo pathway activation (Miller et al., 2012; Mo et al., 2012; Yu et al., 2012). 
These ligands include sphingosine 1 phosphate (S1P) phosphate and lipophosphatidic acid 
(LPA), which signal to activate multiple GPCRs (Yu and Guan, 2013). GPCR signaling-mediated 
YAP control is complex, as some GPCRs are thought to inhibit YAP, whereas others activate it 
(Yu et al., 2012). These recent discoveries have introduced a series of new questions about 
normal Hippo pathway regulation that are currently under investigation by several groups. Proper 
identification of the role for each GPCR Ligand/Receptor pair in YAP regulation is necessary 
before these insights are translated into cancer biology studies, especially considering that many 
of these receptors are expressed in both epithelial and mesenchymal cancer cells.  
 While above regulators have focused on Hippo pathway activation/YAP negative 
regulation, it is increasingly appreciated that growth factor signaling can also affect YAP 
activation either directly or by inhibiting the Hippo pathway (Fan et al., 2013). The current 
understanding is that growth factor signaling (for example, EGFR signaling) affects Hippo 
pathway function by engaging the Ras/MAP kinase and the PI3 kinase signal transduction wings 
(Gumbiner and Kim, 2014).  
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Figure 1. A schematic of the mammalian Hippo Pathway. The Hippo pathway is regulated by 
an extensive group of upstream signals, including factors involved in apicobasal polarity (tight and 
adherens junction), planar cell polarity (Fat signaling), GPCR and mitogenic signals, and 
mechanic cues leading to F-actin/cytoskeletal rearrangements. These upstream signals either 
activate or inhibit the Hippo core kinase cassette, frequently involving intracellular mediators such 
as NF2, KIBRA and EX. The core kinase cassette includes MST1/2, SAV1, LATS1/2 and the 
MOB1 complex. Upon of phosphorylation-mediated kinase activation, LATS1/2 phosphorylate 
and inhibit YAP. Phospho-YAP is recognized by 14-3-3 adaptor proteins and sequestered to the 
cytoplasm, where it can further be targeted for proteasomal-mediated degradation. Phosphatases 
such as PP1/ASPP2 can counteract YAP inhibition. Unphosphorylated YAP translocates into the 
nucleus, binds to transcription factors such as TEAD1-4 and promotes the transcription of many 
pro-proliferation and anti-apoptotic targets. Many members of the Hippo pathway remain 
unknown (designated by a question mark). Arrows indicate activation whereas blunted lines 
indicate inhibition. A more detailed look at known Hippo pathway members can be found in Table 
1.   
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Table 1. Hippo pathway members. Table adapted form (Yu and Guan, 2013) and (Grusche et 
al., 2010)  
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Taken together, the variety of factors and the complex interactions involved in the 
activation or inhibition of the Hippo pathway underscores the importance of YAP/TAZ regulation 
for proper cellular homeostasis. 
Downstream nuclear effectors.  
As mentioned, the role of the Hippo pathway is to inactivate YAP or its homolog TAZ, two 
transcriptional coactivators (Zhao et al., 2010a). YAP is expressed ubiquitously, whereas TAZ 
exhibits more restricted tissue expression. As our work in sarcoma demonstrated aberrant YAP 
(but not TAZ) expression, I am focusing the majority of the description below on YAP.  
As a modular protein, YAP contains several binding motifs, which allow for interaction 
with multiple protein structures (reviewed in Figure 2). However, YAP does not contain a DNA 
binding domain, and is considered a transcriptional coactivator (Sudol and Harvey, 2010). YAP 
functions by enhancing the output of several transcription factors, most notably the TEAD1-4 
proteins. Other known YAP binding partners include the Runx and Smad family members, p73, 
beta catenin, GLI2, and FOXO1 (Shao et al., 2014). Negative regulation of YAP is mainly 
mediated through post-transcriptional modifications and protein-protein interaction mediated 
cytoplasmic sequestration (Zhao et al., 2011b). The Lats/Mob1 kinase complex phosphorylates 
YAP at five different Serine residues. YAP phosphorylation at Serine 127 is the most important 
site, as it creates a docking site for the 14-3-3 adaptor proteins (Zhao et al., 2007). Phospho-YAP 
bound to 14-3-3 can be exported from the nucleus and kept sequestered in the cytoplasm. 
Subsequently, YAP can be phosphorylated by CK1 (Casein Kinase 1). This second 
phosphorylation leads to βTRCP (SCF)-mediated proteasomal degradation.  (Zhao et al., 2010b) 
Yap an also be localized at tight junction complexes (Oka et al., 2010; Zhao et al., 2011a) or 
other complexes associated with the cell membrane (Badouel et al., 2009; Oh et al., 2009) in a 
Hippo pathway-dependent, phosphorylation-independent manner.  
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Figure 2. Schematic of YAP interacting and regulatory domains. (Modified from (Varelas 
2014) and (Sudol et al., 2012)). YAP can be phosphorylated by LATS1/2 at multiple Serine sites. 
Importantly, phospho-S127 is necessary for 14-3-3 binding and cytoplasmic retention, and S397 
for CK1 recognition. Further CK1 phosphorylation leads to YAP degradation.  
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The best understood role for YAP is in directing transcription of genes involved in 
promoting cellular proliferation. To date, multiple players have been identified as direct YAP 
targets, including Cyclin D1 (Cao et al., 2008), Amphiregulin (AREG) (Zhang et al., 2009), 
Connective Tissue Growth Factor (CTGF) (Zhao et al., 2008b), Gli2 (Fernandez et al., 2009), and 
Survivin/Birc5 (Muramatsu et al., 2011), all targets that have been associated with promoting 
tumor growth.  
While the majority of studies have focused on investigating pro-proliferative roles of YAP 
in the nucleus, there is evidence that YAP (particularly the YAP2 isoform) might be promoting cell 
death when binding and consequently stabilizing p73 in the nucleus (Oka et al., 2008). It is 
thought that the YAP-p73 complex is promoted via LATS2 inactivation of the c-Abl kinase 
(Reuven et al., 2013). However, the precise conditions leading to a pro-apoptotic YAP function, 
as well as the downstream targets that mediate apoptotic signaling remain unclear.  
C. The Hippo pathway in cancer 
The propensity for tumorigenesis upon Hippo pathway modulation has been described 
through various animal models. As mentioned earlier, Drosophila screens for proliferation 
inhibitors have been crucial in the delineation of many Hippo pathway members. The tumor-like 
phenotypes in those screens have been described previously (Pan, 2007). In mice, organ-specific 
YAP overexpression or constitutive activation (through a mutation in Serine 127, a LATS 
phosphorylation site) causes tissue overproliferation and consequent carcinogenesis notably in 
liver (Camargo et al., 2007), colon (Avruch et al., 2012), skin (Schlegelmilch et al., 2011), and 
pancreas (Zhang et al., 2014). Additionally, deletions in upstream Hippo pathway factors have 
faithfully recapitulated the tumor phenotypes observed with YAP overexpression. AlbCre; NF2fl/fl 
mice result in hepatocellular carcinoma (HCC), a phenotype that can be abrogated when the mice 
are crossed to YAP1fl/fl mice (Zhang et al., 2010). Mst1/Mst2 deletions as well as Sav1 deletions 
induce liver hypertrophy and eventual HCC progression as well (Lu et al., 2010; Zhou et al., 
2009). LATS1 global deletion showed one of the first instances of spontaneous sarcoma 
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formation (St John et al., 1999). (LATS2fl/fl mice result in embryonic lethality (Yabuta et al., 2007)). 
Recently, Tremblay and colleagues showed that YAP overexpression in muscle can lead to 
spontaneous Embryonal Rhabdomyosarcoma formation (Tremblay et al., 2014). 
D. Targeting the Hippo pathway: YAP inhibition. 
 Due to its functions in cell growth, regeneration and tumor promotion, finding appropriate 
targeting modalities against the Hippo pathway is a highly studied field. Hippo pathway activators 
and inhibitors have been recently surveyed by Johnson and Halder (Johnson and Halder, 2014). 
Inhibiting the upstream Hippo pathway members, or alternatively activating YAP, could be an 
attractive method for inducing tissue regeneration. However, such activation would have to be 
tightly controlled, due to the potent tumorigenic properties of YAP. In cancer, conversely, Hippo 
upstream activators or alternatively YAP inhibitors are sought after, especially in the cases where 
YAP overexpression/activation is thought to drive tumor progression. However, most small 
molecules that target kinases tend to be inhibitory, which would be counterproductive in this 
particular pathway, as it would lead to further YAP activity (Stanger, 2012). While inhibiting 
transcription factor/coactivator complexes poses its own challenges, due to the lack of a 
druggable pocket between protein-DNA interactions, emerging studies are identifying promising 
proof-of-concept YAP inhibitors. In fact, directly inhibiting YAP/TEAD function is preferable, as 
upstream Hippo members are involved in crosstalks with multiple pathways. Table 2 summarizes 
many of these putative YAP inhibitors.  
Part I conclusion 
 While the Hippo pathway key effectors have been extensively studied, the aberrant 
activation or inactivation of Hippo members in the context of cancer is still an evolving field of 
study. Several in vitro, mouse models and patient data studies have demonstrated the propensity 
for tumorigenesis associated with loss of upstream Hippo members, or aberrant YAP activation. 
Many of these studies have focused on epithelial tumors, particularly modeling liver 
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tumorigenesis. Tumors considered mesenchymal in nature however also may rely on aberrant 
Hippo pathway regulation to promote progression. Chapter II describes a new role for Hippo  
Name Mechanism References 
Adrenergic Agonists 
(Dobutamine) 
YAP cytoplasmic retention. 
Unknown mechanism but 
possibly function as Gαs-
coupled GPCR agonists 
(Bao et al., 2011), 
(Park and Guan, 
2013) 
Benzophyrins (Verteporfin) 
Inhibit YAP-TEAD 
interaction, possibly by 
binding to YAP and 
changing its conformation 
(Liu-Chittenden et al., 
2012) 
Statins (Cerivastatin) 
YAP/TAZ inactivation by 
inhibitiing HMG-CoA 
reductase, a key upstream 
enzyme in the mevalonate 
pathway. Ultimately Rho 
inactivation 
(Sorrentino et al., 
2014) 
VGLL4 peptide mimic 
VGLL4 mimic binds to and 
titrates TEAD away from 
YAP binding  
(Jiao et al., 2014) 
Indirect inhibitors 
Rho/Rock inhibitors that 
affect cytoskeleton 
dynamics and GPCR 
signaling 
(Johnson and Halder, 
2014) 
 
Table 2. Summary of potential YAP inhibitors. Partially adapted from Johnson and Halder, 2014. 
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inactivation/YAP activation in sarcomagenesis, emphasizing on FOXM1 as an attractive target for 
sarcoma treatment. 
PART II. MIRNA ROLE IN CELLULAR SURVIVAL UNDER STRESS. 
 While uncontrolled proliferation is a key hallmark of tumorigenesis, evading pro-apoptotic 
signals is equally important for tumor progression (Hanahan and Weinberg, 2000). Uncontrolled 
proliferation creates a microenvironment that is depleted of nutrients and oxygen (O2), or 
“hypoxic” (Semenza, 2007). The angiogenesis switch is necessary for tumor growth (Folkman, 
2002), however, tumor-associated blood vessels are leaky and disorganized (Carmeliet and Jain, 
2011), resulting in heterogeneous availability of nutrients/O2. Tumor cells have managed to co-
opt normal cellular mechanisms to be able to survive under those metabolic stresses (Mucaj et 
al., 2012). Some of these mechanisms include the stabilization of the Hypoxia Inducible factors 
(HIFs) (Keith and Simon, 2007), the activation of the Unfolded Protein Response (UPR) as a 
result of ER stress (Hetz et al., 2013), and various other means of metabolic adaptation (such as 
activation of autophagy, or mutations leading to changed metabolic enzyme functions) which are 
still being elucidated (Cheong et al., 2012). Glioblastoma multiforme tumors experience 
heterogeneous microenvironments with sharp changes in O2 gradients (Vartanian et al., 2014). In 
the next section, I am outlining how cells adapt to low O2, focusing on the Hypoxia Inducible 
Factors (HIFs). 
A. Hypoxia Inducible factors 
 Healthy tissues experience a range of 2% to 9% O2. Tissues grown in less than 2% O2 
are considered to experience hypoxia (Bertout et al., 2008). Hypoxia may occur secondary to 
necrosis or aberrant neovascularization resulting in poor perfusion. Additionally, cancer cells may 
proliferate rapidly enough to outstrip their blood supply (Majmundar et al., 2010). Cells adapt to 
changes in O2 availability by altering gene expression of crucial metabolic enzymes in order to 
counter changes in nutrient availability and redox status. This response is mediated, in part, by 
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O2 – labile transcription factors hypoxia-inducible factors HIF-1α and HIF-2α, key regulators of 
cellular adaptation to hypoxic stress (Keith et al., 2012). 
 Comprised of an O2 -sensitive α subunit and constitutively expressed β subunit, HIFs are 
primarily regulated through post-translational modification and stabilization. Under normal O2 
tensions, prolyl hydroxylase domain enzymes (PHDs) hydroxylate two conserved proline residues 
in the HIF-α subunits. Upon hydroxylation, the HIFα subunit is poly-ubiquitinated for proteasomal 
degradation via the von Hippel-Lindau (VHL) tumor suppressor E3 ligase complex (Cockman et 
al., 2000; Jaakkola et al., 2001). Upon low O2 levels, PHDs no longer hydroxylate the HIFα 
subunit, which leads to HIFα stabilization and nuclear translocation. In the nucleus, HIFα 
transcription factors dimerize with their obligate binding partner, HIFβ (also known as ARNT), and 
the HIFα/ARNT complex drives the transcription of numerous factors important for survival under 
low O2, as well as for migration/invasion away from low O2 areas. These factors include, but are 
not limited to: VEGFA, CA9, BNIP3, LOX, SERPINE, PGK1, GLUT1 (Dayan et al., 2006; 
Pouyssegur et al., 2006). 
Increased HIF activity is evident in cancer, as cancer cells maintain rapid proliferation, 
even in the absence of adequate O2 and nutrient availability. Adaptive metabolic changes allow 
continued biosynthesis and cell growth in the setting of decreased access to O2. As cancer cells 
divide and outstrip O2 and nutrient supplies, HIF activation allows modulation of cell metabolism 
and gene expression to adapt to the ever-changing landscape of the tumor microenvironment. 
HIF expression is an important prognostic factor, as levels associate closely with poor patient 
outcomes in a variety of cancers (Semenza, 2007). 
 
B. MiRNA biology. 
 While only ~22 nucleotides in length, mature miRNAs control a wide-spanning array of 
targets, whose modulation can cause profound changes within a cell (Ambros, 2004). These 
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small noncoding RNAs originate from genomic DNA and function by negatively regulating their 
targets in a post-transcriptional manner. First described in C. elegans as controller of 
developmental cues (Lee et al., 1993), miRNAs are now thought to modulate a range of cellular 
functions, including proliferation, differentiation, and cell death. Fig. 3 summarizes miRNA 
biogenesis, and the concept that aberrant over and underexpression of miRNAs can lead to 
deleterious consequences, including tumor progression (Esquela-Kerscher and Slack, 2006b). 
 Yi and Fuchs compare miRNA function to that of a rheostat, which modulates and fine-
tunes signals in the cell, potentially to achieve homeostasis, or a particular goal, such as stem cell 
maintenance, proliferation control, or differentiation (Yi and Fuchs, 2011). This notion is 
supported by the fact that, while miRNAs only slightly attenuate their target levels, it is estimated 
that they may regulate more than 30% of the mammalian genome (Bartel, 2009; Esquela-
Kerscher and Slack, 2006b). It is thus tempting to hypothesize that miRNAs are key players in 
stress response signaling. In fact, several miRNAs have been implicated in responses to stress. 
For example, miR-210 is considered the “master hypoxamiR” as low O2 can upregulate miR-210 
expression. In turn, miR-210 targets a wide range of factors involved in cell cycle, mitochondrial 
respiration, angiogenesis, and DNA repair, ultimately giving rise to cellular changes that allow for 
hypoxic adaptation (Chan et al., 2012). Similarly, miR-451 has been implicated in metabolic 
stress adaptation (Godlewski et al., 2010) while miR-211 has been shown to elicit pro-survival 
mechanisms under ER stress (Chitnis et al., 2012).  
 While miRNA expression can be regulated to respond to stress, similar effects can be 
observed when miRNAs are aberrantly expressed, as in the case of many cancers. Recently, our 
lab has shown that clear renal cell carcinomas (ccRCC) express low levels of miR-30c-2-3p and 
miR-30a-3p in order to enhance HIF-2α expression, and elevating the oncogenic potential of 
ccRCC (Mathew et al., 2014a). Similarly, investigating the effects of diminished miRNA levels on 
glioblastoma survival under hypoxia, our laboratory has shown that mesenchymal subtype 
glioblastomas express the lowest levels of miR-218, even when compared to other glioblastoma 
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subtypes. As miR-218 targets a series of proteins involved in a Receptor-Tyrosine Kinase/HIF 
signaling cascade, low miR-218 levels allow for uncontrolled expression of that signaling axis, 
which promotes survival under a hypoxic/ischemic microenvironment (Mathew et al., 2014b). 
 Among miRNAs differentially regulated in glioblastoma, miR-124 is one of the most 
decreased at the tissue level, both when comparing glioblastoma tissue to adjacent normal 
tissue, as well as when we compare glioblastomas (grade IV gliomas) to lower grade gliomas or 
to gliosis tissues (Silber et al., 2008b). miR-124 is one of the best studied miRNAs in the brain, 
and a key modulator of neuronal differentiation (Makeyev et al., 2007a). Thus, differentially 
expressed miR-124 in the context of the brain has important consequences, and in the case of 
glioblastoma, miR-124 can become an attractive tool for identifying key factors involved in glioma 
progression. Several studies have ectopically expressed miR-124 in glioblastoma cells and 
demonstrated changes in proliferation, migration, invasion, and inflammation. The previously 
examined roles of miR-124 in normal development and in glioblastoma are summarized in Fig. 4.  
Part II conclusion 
 Solid tumors have adopted multiple mechanisms to survive stressful microenvironments, 
including the modulation of miRNA levels. While multiple roles for miR-124 in glioblastoma have 
been previously addressed, very little is known about how miR-124 affects cells grown under 
limiting O2 and nutrients. To that end, Chapter III introduces a new phenotype where miR-124 
elicits increased death in cells grown under hypoxic/ischemic conditions, thereby counteracting 
glioblastoma pro-survival responses to stress. 
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Figure 4. Multiple roles for miR-124 in normal brain tissues and in glioblastoma.  
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CHAPTER 2 
Deregulation of the Hippo Pathway in soft tissue sarcoma promotes 
tumorigenesis via YAP/FOXM1 signaling 
 
Sections of this chapter have been adapted from the following manuscript: “Deregulation 
of the Hippo pathway in soft tissue sarcoma promotes FOXM1 expression and tumorigenesis” 
Eisinger, T.S., Mucaj V., Biju K.M., Nakazawa M.S., Yoon S.S., Park K.M., Gerecht S., and 
Simon M.C., in Submission.  
 
SUMMARY 
The role of the Hippo pathway is unclear in most soft tissue sarcomas (STS). Recent studies 
have suggested that inactivation of the Hippo pathway, resulting in over-expression of the 
transcriptional co-activator Yes-activated protein (YAP), may drive proliferation in these tumors 
but the mechanism is unclear. In other tumor contexts increased YAP expression has been 
shown to facilitate expression of the pro-proliferation transcription factor, FOXM1. FOXM1 and 
many of its transcription targets including MYC, LOX, and VEGF have been directly associated 
with tumorigenesis. In this chapter, I present data gathered from human sarcoma patients and a 
novel autochthonous mouse sarcoma model to show that YAP-mediated FOXM1 expression is 
necessary for sarcoma proliferation and tumorigenesis. Additionally, we have uncovered a 
previously unknown mechanism wherein FOXM1 directly interacts with the YAP transcriptional 
complex via TEAD1, resulting in potential co-regulation of a variety of pro-proliferation 
transcription targets. Finally, we have found that pharmacologic inhibition of FOXM1 decreases 
tumor size in vivo, suggesting that FOXM1 may be an attractive therapeutic target for the 
treatment of sarcomas.  
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INTRODUCTION 
Soft tissue sarcomas (STS) are heterogeneous mesenchymal tumors detected annually 
in more than 200,000 people worldwide (Taylor et al., 2011). STS are comprised of a large subset 
of histologically distinct tumor types with fibrosarcoma, liposarcoma, and undifferentiated 
pleomorphic sarcoma (UPS) among the most commonly diagnosed in adults.  UPS in particular is 
an aggressive metastatic STS subtype. As its etiology is currently unknown, UPS is a diagnosis 
of exclusion, and the lack of elucidated complex genetic drivers underlying human UPS has made 
therapeutic intervention difficult (Kelleher and Viterbo, 2013; Taylor et al., 2011). Metastasis in 
UPS patients likely occurs due to hyper-proliferation of the primary tumor, which results in a 
hypoxic microenvironment that promotes tumor cell dissemination (Eisinger-Mathason et al., 
2013). An improved understanding of genetic aberrations responsible for sarcoma initiation and 
progression is essential for the future development of effective targeted therapies. 
To date, there are few disease-specific treatments to offer sarcoma patients. Current 
therapeutic modalities include surgery, radiotherapy and cytotoxic chemotherapy (Taylor et al., 
2011). Among these, radical surgeries are the most effective means of treating sarcoma (Linehan 
et al., 2000). However, in some cases, tumor-ablating surgery is not possible and local 
recurrences appear. Furthermore, primary tumor resections do not eliminate cells that may have 
disseminated prior to surgery. More conservative surgeries, combined with effective targeted 
inhibitors of proliferation and/or migration would significantly improve patient prognosis and 
quality of life.  
The mesenchymal origins of sarcoma present an inherent challenge to the development 
of sarcoma-specific therapeutics. Compared with epithelial tumors, sarcomas are significantly 
understudied. As a result, mesenchymal tumor initiation and progression are poorly understood. 
Recent efforts by The Cancer Genome Atlas (TCGA) and other tissue banking resources that 
accumulate and process patient samples have provided invaluable tools for probing molecular 
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pathways underlying sarcomagenesis.  Using these tools, we have uncovered a role for aberrant 
Hippo pathway signaling in fibrosarcoma, UPS, and potentially several other sub-types of STS. 
Given the importance of this conserved pathway in organogenesis, Hippo inactivation 
and constitutively active YAP could be potent tumor promoting mechanisms. In fact, NF2 
mutation or loss of function have been reported in Neurofibromatosis type II lesions 
(schwannomas, meningiomas, ependymomas), malignant mesothelioma, and infrequently in 
other carcinomas, albeit infrequently (Harvey et al., 2013; Mizuno et al., 2012; Sekido et al., 1995; 
Yoo et al., 2012). With the exception of NF2 mutations, no other Hippo pathway mutational 
events have been reported in cancer (Harvey et al., 2013). However, genomic 
deletions/amplifications and gene expression changes have been detected throughout Hippo 
signaling. For example, decreased SAV1 activity has been implicated in clear cell renal cell 
carcinoma progression (Matsuura et al., 2011). In breast cancer, 11q22 chromosomal 
amplifications lead to YAP overexpression, thereby bypassing Hippo upstream control 
(Overholtzer et al., 2006). Amplifications at the YAP locus have also been described in 
medulloblastomas (Fernandez et al., 2009). However, little is known about the status of the Hippo 
pathway in STS, although MST1/2 appear to be epigenetically silenced through promoter 
hypermethylation in a limited number of sarcoma patient samples (Seidel et al., 2007). Of note, 
YAP overexpression has recently been reported in both alveolar and embryonic 
rhabdomyosarcoma (Crose et al., 2014; Tremblay et al., 2014). 
YAP modulation is a powerful regulator of tumor cell proliferation due to the 
transcriptional changes associated with its activity. Many YAP/TEAD targets have been 
previously associated with tumor progression, including BIRC5, CCND1, and FOXM1 (Kim et al., 
2013; Mizuno et al., 2012; Pan, 2010; Zhao et al., 2011b; Zhao et al., 2008c). In particular, 
YAP/TEAD directly bind the FOXM1 promoter, inducing its expression in a model of malignant 
mesothelioma (where upstream NF2 mutations are common) (Mizuno et al., 2012). FOXM1 is a 
winged helix-turn-helix transcription factor important for cell cycle progression and proliferation 
23 
 
(Wierstra, 2013). FOXM1 is required for tumor formation in multiple epithelial cancers, including 
hepatocellular carcinoma (HCC), wherein FOXM1 increases cell proliferation by enhancing 
Cdc25b phosphatase expression (Kalinichenko et al., 2004). FOXM1 activity is inhibited by direct 
interaction with p19ARF, whereby p19ARF targets FOXM1 and other signaling molecules to the 
nucleolus preventing them from engaging in transcriptional upregulation of factors involved in 
proliferation (Kalinichenko et al., 2004). In addition, FOXM1 is negatively regulated through the 
p53 (Pandit et al., 2009) and RB pathways (Wierstra and Alves, 2006). Therefore, FOXM1 is 
highly expressed in a variety of human cancer cells due to loss of tumor suppressive proteins, 
and aberrant expression of pro-mitogenic factors (Halasi and Gartel, 2013) leading to 
overproliferation and metastasis (Park et al., 2011). 
 To probe the relationship between the Hippo pathway and FOXM1 in sarcomagenesis, 
we employed a variety of approaches, including multiple mouse models of UPS and cell lines 
derived from these tumors. LSL KrasG12D/+; Trp53fl/fl (KP) and LSL KrasG12D/+; Ink4/Arffl/fl mice 
recapitulate UPS (Eisinger-Mathason et al., 2013; Kirsch et al., 2007) allowing the study of 
downstream molecular signaling factors that control sarcomagenesis. Coupled with patient data, 
we have identified pro-proliferation factors and pathways aberrantly regulated in UPS, which can 
be targets for therapeutic intervention. 
While previous studies have implicated YAP and FOXM1 as critical factors promoting 
epithelial tumorigenesis, little evidence has suggested that the Hippo pathway and its 
downstream effectors are aberrantly regulated in STS. Here, we identify key Hippo pathway 
members whose levels are decreased in TCGA sarcoma patient samples. We show that YAP is 
nuclear and highly overexpressed in UPS and liposarcomas leading to elevated FOXM1 across 
these subtypes. Both genetic and pharmacologic inhibition of YAP/TEAD and FOXM1 result in 
sarcoma cell proliferation defects, suggesting that these targets represent a promising therapeutic 
intervention for this mesenchymal disease. 
MATERIALS AND METHODS  
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Cell culture, drug treatment, and lentiviral transduction 
 HT-1080 and HEK-293T cell lines were purchased from ATCC (Manassas, VA, USA). KP 
and KIA cells were derived from KP and KIA tumors, as previously described (Eisinger-Mathason 
et al., 2013; Kirsch et al., 2007). Cells were treated with 1-2 µM Thiostrepton or 1 µM Verteporfin 
(Sigma-Aldrich, St. Louis, MO, USA), in dimethyl sulfoxide, diluted in DMEM culture media. 
Verteporfin was replenished every 24 hours. For shRNA-mediated knockdown of Yap1, YAP1, 
Foxm1, and FOXM1 constructs in the pLKO.1 background vector was used (GE lifesciences). 
Scramble shRNA was obtained from Addgene. shRNA plasmids were packaged using the third-
generation lentivector system (VSV-G, p-MDLG, and pRSV-REV ) and expressed in HEK-293T 
cells. TRCN: Yap1:0000095867 , YAP1: 0000107268, Foxm1:0000084776, and FOXM1: 
0000015546 Supernatant was collected at 24 and 48 hours post transfection, and subsequently 
concentrated using 10-kDa Amicon Ultra-15 centrifugal filter units (Millipore, Billerica, MA, USA). 
Over-expression plasmids used were pPGS-3HA-TEAD1 (plasmid 33055, Addgene), pcDNA3-
Flag-FOXM1 (MJ Reginato, Drexel University) and pcDNA3 was used as the empty vector 
control.  
Bioinformatics analysis 
Level 3 data comprising regions/segments with altered copy number were downloaded 
from the TCGA Data portal (data last updated as of May 15, 2014, (https://tcga-
data.nci.nih.gov/tcga/tcgaCancerDetails.jsp?diseaseType=SARC&diseaseName=Sarcoma)). The 
data was analyzed using the Partek 6.6 software (St. Louis, Missouri, USA). Briefly, sample files 
were lined up and concatenated. Subsequently, the thresholds for amplification/deletion were set 
at 0.55 and -0.4, for amplification and deletion, respectively. These cutoffs were based on 
previously published literature. Tumor samples for copy number analysis consisted of 152 
samples total, with 150 primary samples and 2 recurrences. The results obtained from blood 
samples and normal controls were eliminated from the analysis as they contained no 
amplifications or deletions. The Venn diagram was generated using the BioVenn web application 
(http://www.cmbi.ru.nl/cdd/biovenn/). Microarray data were downloaded through the Oncomine™ 
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Research premium edition (Life Technologies, Carlsbad, CA, USA) software version 4.5 
(https://www.oncomine.org) Data was downloaded form microarrays associated with the 
Nakayama et al., 2007 (Nakayama et al., 2007) and Detwiller et al. 2005, (Detwiller et al., 2005) 
manuscripts. GIST tumors were excluded from our analysis due to their distinct histological and 
genetic features as well as their unique tissue of origin.  
Immunoblots and qRT-PCR 
Protein lysate prepared in SDS/Tris pH 7.6 lysis buffer, separated by electrophoresis in 
10% SDS–PAGE gels, transferred to nitrocellulose membrane and probed with the following 
antibodies: rabbit anti-YAP1, rabbit anti-GAPDH, rabbit anti-HA (Cell Signaling Technology, Inc., 
Danvers, MA, USA), rabbit anti-FOXM1 (Santa Cruz Biotechnology, Inc., Dallas, TX, USA). 
Representative immunoblots from multiple independent experiments are presented. Total RNA 
was isolated from tissues and cells using the RNeasy Mini Kit (Qiagen, Germantown, MD, USA) 
or the TRIzol reagent protocol (Life Technologies, Carlsbad, CA). Reverse transcription of mRNA 
was performed using the High-Capacity RNA-to-cDNA Kit (Life Technologies, Carlsbad, CA). 
qRT-PCR was performed using a ViiA7 apparatus and Taq-Man “best coverage” primers (Life 
Technologies, Carlsbad, CA). 
Immunostaining and Imaging 
Immunohistochemistry assays were performed on 5-µm sections according to standard 
protocols. The following antibody concentrations were used: YAP 1:100 (Cell Signaling 
Technology, Inc., Danvers, MA, USA), FOXM1 1:100 and TEAD1 (Novus Biologicals, Littleton 
CO), Ki67 1:100 (Abcam, Cambridge, UK). Images were taken using a Leica 500 microscope 
(Leica, Solms, Germany) and analyzed using Photoshop CS3 (Adobe Systems, San Jose, CA). 
IHC of human sarcoma samples was done using core biopsy arrays (US Biomax Inc, Rockville, 
MD) array #s SO801a and SF961.  
Proliferation assays 
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For drug studies cells were plated and incubated overnight in tissue culture dishes. The 
next day the appropriate drug diluted in growth media was added to the cells. Cells were 
trypsonized, re-suspended, in PBS and counted daily for 4 days using a hemocytometer. For 
shRNA studies cells were incubated with virus for 48 hours then trypsonized and re-plated 
followed by daily counting for four days. Cells were analyzed for shRNA efficacy by immunoblot 
analysis or qRT-PCR. 
Immunoprecipitation 
HT-1080 cells were transiently transfected using Fugene 6 (Life Technologies, Carlsbad, 
CA) with Flag-FOXM1 and either pcDNA3vector control, V5-YAP, or HA-TEAD1 (8 µg total DNA). 
After 48 hours of incubation cells were washed with PBS, scraped, spun, and re-suspended in 
lysis buffer containing 1% Triton-X and protease inhibitors. Equal amounts of input lysate were 
added to 75 µL of anti-Flag M2 coated magnetic beads (Sigma-Aldrich, St. Louis, MO, USA). 
Beads and lysate were incubated overnight with rocking at 4oC. Beads were washed, and then 
boiling with loading buffer for 5 minutes eluted the protein. The sample was removed from the 
beads by magnetic separation and then run on a 10% SDS-PAGE gel for immunoblot analysis.   
Mouse Models 
All experiments were performed in accordance with the National Institutes of Health 
guidelines and approved by the University of Pennsylvania Institutional Animal Care and Use 
Committee. FOXM1fl/fl mice were crossed with KP mice to create KPF mice. Foxm1fl/fl 
(Kalinichenko et al., 2002) and KP (Kirsch et al., 2007) mouse generation has been previously 
described. Tumors were generated by intramuscular injection of a calcium phosphate precipitate 
of Ad-Cre (Gene Transfer Vector Core; University of Iowa, Iowa City, IA, USA) into the left 
gastrocnemious muscle of 8-16 week old mice.  Mice were sacrificed at maximal permitted tumor 
burden. For sub-cutaneous transplant tumors 1 x 106 KP or HT1080 cells were injected 
subcutaneously into the flanks of 6 weeks old nu/nu mice (Charles River Laboratories, Malvern, 
PA). In each experiment, ~10 mice per experimental group were used with each mouse bearing 
two subcutaneous tumors. Animals were euthanized within 20-30 days of injection.  Tumor 
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volume was calculated using the formula (ab2)π/6, where a is the longest caliper measurement, 
and b is the shortest. 
In vivo drug treatment  
Thiostrepton was encapsulated into micelles assembled from amphiphilic lipid-PEG 
(polyethylene glycol) molecules as previously described (Wang and Gartel, 2011). Anaesthetized 
mice were retro-orbitally injected with PBS, 7.5 mg/kg, or 15 mg/kg Thiostrepton encapsulated 
micelles every third day for 3.5 weeks.   
Statistical analysis 
All statistical analyses were performed using the GraphPad Prism software (La Jolla, CA, 
USA). Data are represented as mean±s.e.m. Student’s t-test was performed to establish whether 
a difference between two values is statistically significant, with statistical significance are 
designated with a * an defined as p<0.05.  
RESULTS 
Deregulation of the Hippo pathway in human sarcomas 
Abnormal regulation of Hippo pathway activity can lead to increased cell proliferation and 
tumorigenesis.  To determine whether Hippo pathway genetic aberrations occur in STS, we 
queried the TCGA sarcoma database for copy number variations in the upstream drivers of Hippo 
signaling. Our analysis revealed that 41% of sarcoma samples deposited in the TCGA database 
contain deletions in one or more of these Hippo pathway components, including NF2, SAV1, and 
LATS2 (Fig. 5A). Most of the genetic deletions were in LATS2, while 20% of affected tumors 
contained deletions of multiple Hippo regulators (Fig. 5B). Such genetic changes would be 
anticipated to result in stabilization and nuclear translocation of the Hippo pathway downstream 
effector, YAP. Immunohistochemical (IHC) analysis of human tissue samples showed that YAP 
levels are dramatically increased in UPS tumors, compared with normal skeletal and arterial 
tissue (Fig. 6A). Transcriptionally active YAP is localized to the nucleus, and high magnification 
analyses of human tissue cores (Fig. 6A) clearly demonstrated active YAP in the nuclei of UPS 
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and liposarcoma (LS) samples compared to normal arterial muscle tissue (Fig. 6B). These data 
suggest that Hippo pathway inhibition and subsequent stabilization of active YAP may be an 
important mechanism in sarcomagenesis.  
YAP inhibition results in decreased sarcoma cell proliferation in vitro and in vivo 
To determine the role of YAP in STS we initiated cell-based proliferation studies in 
murine and human sarcoma cell lines.   Murine sarcoma cells were derived from the 
autochthonous KrasG12D/+;Trp53fl/fl (KP) and KrasG12D/+;Ink4a/Arffl/fl (KIA) models of UPS. Tumors 
that develop in these mice, following Adeno-Cre virus injection into the left gastrocnemius muscle, 
recapitulate human UPS morphologically and histologically, while harboring similar gene 
expression profiles (Eisinger-Mathason et al., 2013; Kirsch et al., 2007; Mito et al., 2009).  
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Figure 5. Hippo pathway deregulation in human sarcoma. A) TCGA STS copy number data 
showing percentage of Hippo pathway deletions. N=150 STS patients. B) Venn diagram 
delineating number of common and unique deletions in the 62 STS patient samples containing 
LATS2, SAV1, or NF2 deletions.  
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Figure 6. Deregulated YAP expression in human sarcoma. A) Immunohistochemical staining 
for YAP levels in normal and STS patient sample biopsy cores. B) Magnification showing YAP 
localization in biopsy cores from D. Scale bar=100 µM. Karin Eisinger contributed this figure.  
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Additionally, hind limb tumors successfully metastasize to the lung, mirroring human 
UPS. To determine the role of YAP in sarcoma cell proliferation we employed specific lentiviral 
shRNAs. Yap depletion significantly reduced KP and KIA cell proliferation in vitro (Fig. 7A), with 
similar results obtained for human HT-1080 fibrosarcoma cells using an independent shRNA (Fig. 
7B). Based on these findings we proceeded to define the role of YAP in tumor formation. We 
injected 1 X106 KP cells, transduced with control or YAP- specific shRNA, into the flanks of nude 
mice in order to generate allograft tumors. YAP deletion resulted in significantly decreased tumor 
volume (Fig. 7C) and final tumor weight (Fig. 7D). IHC analysis of control and Yap-silenced 
tumors showed that Yap ablation decreases the number of Ki67+ cells by ~40% (n=4 samples 
per condition, P=0.0005), indicating decreased proliferation (Fig. 7E) consistent with our in vitro 
findings  (Fig. 7A,B).  The YAP inhibitor Verteporfin (VP) prevents its interaction with constitutively 
nuclear binding partners, TEAD1-4, thereby inhibiting transcriptional activation of YAP/TEAD 
targets (Liu-Chittenden et al., 2012).  Consistent with Yap inhibition via shRNA, treatment with 
1µM VP dramatically reduced sarcoma cell proliferation (Fig. 8A-C). qRT-PCR analyses of VP 
treated KP cells revealed that Yap targets including, Lox, Cdkn3, Plk1, Foxm1, and Birc5, 
exhibited decreased expression 48 hours later (Fig. 8D). Similar results were obtained by VP 
treatment of KIA cells (Fig. 8E) as well as shRNA-mediated Yap inhibition, although, surprisingly 
FOXM1 mRNA levels show a trend in decrease that is not statistical significant (Fig. 8F). From 
these data we noted that many of the downregulated mRNAs (Lox, Cdkn3, Plk1, and Birc5) were 
also targets of FOXM1-mediated transcription, in addition to being YAP targets. Based on this 
finding, we investigated the possibility that FOXM1 is an essential component of the YAP 
transcriptional program wherein YAP activation controls FOXM1 expression, and as a result, 
impacts FOXM1 transcriptional output (i.e. LOX, CDKN3, PLK1, BIRC5). Initially, we confirmed 
that YAP regulates FOXM1 protein expression. Inhibition of YAP by VP treatment (Fig. 9A) and 
with YAP- specific shRNA (Fig. 9B) decreased FOXM1 protein levels in HT-1080, KIA, and KP 
cells.  Consistent with previous reports, VP had no reproducible effect on YAP protein levels (Liu-
Chittenden et al., 2012).  We conclude that YAP is a major regulator of FOXM1 expression in  
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Figure 7. YAP inhibition decreases proliferation in vitro and in vivo. A) Yap knockdown via 
shRNA transduction inhibits proliferation in KIA and KP cells P<0.0006 for both cell types at day 
4. B) YAP silencing in human sarcoma (HT-1080 cells) inhibits proliferation as in (A) P<0.005 at 
day 4. C) We subcutaneously injected 1X106 KP cells bearing control or control shRNA into nu/nu 
mice. YAP deletion inhibits tumor growth. Scr shRNA n=9; Yap shRNA n=8; P<0.0002 at day 18. 
D) Tumor weight is decreased in Yap-deleted tumors P=0.009. E) IHC of YAP and Ki67 in control 
and Yap-deleted tumors showing a loss of proliferation associated with Yap silencing. Scale 
bar=100 µM. Karin Eisinger and Kevin Biju assisted with the completion of this figure.  
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Figure 8. VP treatment affects cell count and decreases pro-proliferation targets. A) 
Treatment of HT-1080 cells with 1 µM VP for four days inhibited proliferation P=0.017 at day 4. B) 
KIA cells treated as in (A) P=0.013 at day 4. C) KP cells treated as in (A) P=0.003 at day 4. D) 
qRT-PCR analysis of KP cells 1 µM VP for 48 hours shows that VP treatment decreases mRNA 
levels of YAP transcriptional targets: Lox P=0.007; Cdkn3 P=0.001; Plk1 P=0.009; Foxm1 
P=0.017; Birc5 P=0.0003. E) KIA cells treated with 1µM VP for 48 hours showed decreases in 
FOXM1 target mRNA expression including Lox P=0.013; Cdkn3 P=0.001; Vegfa P=0.047; Plk1 
P=0.012; Foxm1 P=0.05; Birc5 P=0.004. F) KP cells treated with Yap shRNA show decreases in 
mRNA expression of Foxm1 and FOXM1 targets including Lox P=0.003 and Birc5 P=.009. Karin 
Eisinger and Kevin Biju assisted with the completion of this figure. 
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Figure 9. YAP inhibition decreases FOXM1 expression. A) Immunoblot analysis of HT-1080, 
KIA, and KP cells treated with 1 µM VP for 4 days. B) Immunoblot analysis of FOXM1 expression 
in YAP deleted KP, KIA and HT1080 cells.  
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sarcoma cells and that mechanisms by which YAP promotes sarcoma cell proliferation and 
tumorigenesis may require FOXM1. 
FOXM1 is highly expressed in human sarcomas 
In order to determine the importance of FOXM1 as a downstream effector of the Hippo 
pathway in human sarcoma, we investigated FOXM1 expression levels in human tumor samples. 
Based on the observation that the Hippo pathway is deregulated in STS (Fig.5) we predicted that 
YAP target gene levels, specifically FOXM1, would be elevated in patient samples. Using 
publically available microarray analyses of STS from Detwiller et al. (Detwiller et al., 2005) and 
Nakayama et al. (Nakayama et al., 2007) we compared the levels of FOXM1 mRNA in normal 
and STS tissues (Fig. 10A,B). The list of individual tumor subtypes and associated FOXM1 levels 
can be found in Table 3. FOXM1 was dramatically upregulated in a variety of human sarcoma 
subtypes including fibrosarcoma, leiomyosarcoma, UPS, and liposarcoma relative to normal 
tissues. Interestingly, FOXM1 levels in synovial sarcoma are less uniform suggesting that 
synovial sarcomas may employ alternate mechanisms of proliferation control. We used the 
Oncomine™ co-expression analysis tool to identify genes whose expression paralleled FOXM1 in 
STS, and we compared the top 40 genes with known and potential YAP targets identified in the 
literature and a publically available microarray dataset of genes downregulated upon YAP 
inhibition in human malignant mesothelioma cells (Mizuno et al., 2012). Of the top 40 genes co-
expressed with FOXM1 in the Detwiller et al. database, 13 are also putative YAP targets (Fig. 
11A,B). Similarly, 15 these top 40 genes identified in the Nakayama et al. database are putative 
YAP targets (Fig. 12A,B). 60% of these top targets are identical between the two databases. 
These results are consistent with the hypothesis that YAP/TEAD targets are upregulated in STS, 
most likely as a result of Hippo pathway dysregulation. Importantly, we showed that FOXM1 is 
consistently upregulated in a variety of STS subtypes, suggesting that increased FOXM1 may be 
a common driver of proliferation in sarcoma.  
FOXM1 promotes proliferation in sarcoma cells  
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Figure 10. FOXM1 is highly expressed in human sarcoma. A) FOXM1 levels obtained from 
Oncomine™ analysis of the Detwiller et al., 2005 microarray showed elevated FOXM1 mRNA 
levels in the indicated sarcomas compared with normal tissue all P < 1 x 10-7.  B) Oncomine™ 
analysis of the Nakayama et al., 2007 microarray all P < 0.014.  
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Table 3. Sarcoma subtypes included in expression analysis. Lists of the sarcoma subtypes 
(in order) included in Oncomine-based gene expression analysis from Detwiller et al., and 
Nakayama et al.  
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Figure 11. YAP target co-expression with FOXM1 in Detwiller et al. A) Oncomine analysis of 
targets co-expressing with FOXM1 in the Detwiller et al., 2005 microarray. Arrows indicate targets 
that are also controlled by YAP; targets summarized in (B). B) Table delineating YAP targets co-
expressed with FOXM1 in the Detwiller et al., 2006 microarray in sarcoma, including correlation 
coefficients of co-expression.  
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Figure 12. YAP target co-expression with FOXM1 in Nakayama et al. A) Oncomine analysis 
of targets co-expressing with FOXM1 in the Nakayama et al., 2007 microarray. Arrows indicate 
targets that are also controlled by YAP; targets summarized in (B). B) Table delineating YAP 
targets co-expressed with FOXM1 in the Nakayama et al., 2007 microarray in sarcoma, including 
correlation coefficients of co-expression.  
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Figure 13. FOXM1 drives proliferation in sarcoma cells. A) Proliferation assay of HT-1080 
cells expressing empty vector or Flag-FOXM1 constructs. P = 0.019. B) Immunoblot of FOXM1 
and YAP levels 4 days post Flag-FOXM1 overexpression. C) Proliferation analysis of HT-1080 
and KIA cells expressing scrambled (Scr) or FOXM1 shRNA: HT-1080 P =0.042 at day 4; KIA 
P=0.012 at day 4.  D) Immunoblot of FOXM1 and YAP levels 4 days post FOXM1 knockdown. 
Karin Eisinger contributed this figure.  
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As a key transcriptional output of the Hippo pathway and a known driver or proliferation in a 
variety of cancer models, we investigated the role of FOXM1 in sarcoma cell growth.  We 
performed a combination of over-expression and shRNA-mediated FOXM1 ablation experiments. 
Human Flag-FOXM1was introduced into HT-1080 cells, which exhibit a slower rate of proliferation 
and lack p53 mutations or deletions that could elevate endogenous FOXM1 levels. Expression of 
Flag-FOXM1 increased proliferation in these cells (Fig. 13A) while having no effect on 
endogenous YAP expression levels (Fig. 13B). Consistent with these findings, shRNA-mediated 
silencing of FOXM1 significantly inhibited proliferation of both human and murine sarcoma cells 
(Fig. 13C,D). We hypothesized that reintroduction of Flag-FOXM1 might partially rescue YAP-
dependent growth defects in sarcoma cells. However, exogenous FOXM1 had no effect on 
proliferation of sarcoma cells expressing a YAP-specific shRNA (Fig. 14A,B). Based on these 
data the overlap of YAP and FOXM1 target genes, we investigated the possibility that FOXM1 
interacts directly with the YAP complex to promote transcription in sarcoma cells. If a physical 
interaction between FOXM1 and YAP were essential for YAP/TEAD activity then exogenous 
FOXM1 would not be able to “rescue” proliferation in the absence of YAP. We performed Flag-
FOXM1 IP studies in HT-1080 cells expressing empty vector, V5-YAP, or HA-TEAD1 (Fig. 14C). 
While FOXM1 failed to bind YAP, it interacted strongly with TEAD1. This observation suggests 
that a physical association between FOXM1 and the YAP/TEAD complex occurs at the promoters 
of target genes, providing a likely explanation for the inability of FOXM1 to rescue YAP-deficient 
cell proliferation. To determine if FOXM1 can interact with the YAP/TEAD complex at target gene 
promoters in humans, we queried ChIP-seq data available through the Encyclopedia of DNA 
Elements (ENCODE) project and UCSC Genome Browser (http://genome.ucsc.edu/ENCODE/). 
Sequence analyses of up to 20 kilobases upstream of the transcriptional start sites (TSS) of 24 
independent putative YAP/TEAD or FOXM1 targets was performed, and queried for TEAD or 
FOXM1 consensus binding sites. FOXM1 and TEAD binding sites were considered adjacent if 
they were within 200 bases of each other. Target genes containing both FOXM1 and TEAD 
consensus sites were assessed to determine if the sites were adjacent, suggesting direct  
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Figure 14. Evidence for YAP/TEAD/FOXM1 interaction. A) Rescue Proliferation analysis of 
HT-1080 cells expressing YAP shRNA or Scr shRNA as well either a Flag-FOXM1 over-
expression constructor empty vector Scr/vector shRNA vs. YAP shRNA/vector P <0.02 at day 4; 
Scr/vector vs. Scr/Flag-FOXM1 P <0.02 at day 4. B) Immunoblot showing YAP and FOXM1 
levels from day 4 of proliferation assay in (A). C). Immunoblot showing HA, YAP, and Flag-
FOXM1 levels upon immunoprecipitation with anti-Flag antibody-coated beads. D) Schematic of 
TEAD and FOXM1 binding sites upstream of the transcription start sites (TSS) for FOXM1 (1), 
PLK1 (2), and CDKN3 (3). Each schematic represents an example of TEAD1 only binding site 
presence (1), adjacent TEAD/FOXM1 sites (2) and non-adjacent TEAD/FOXM1 sites (3). Blue = 
TEAD binding site. Red = FOXM1 binding site. E) Table dividing 24 FOXM1 or YAP/TEAD targets 
into groups based on location and identity of the binding sites (adjacent TEAD/FOXM1 binding 
sites, non-adjacent TEAD/FOXM1 binding sites, TEAD sites only, and FOXM1 sites only). Karin 
Eisinger assisted with the completion of this figure. 
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interaction of FOXM1 with TEAD, or non-adjacent indicating potentially independent regulation by 
both factors. A schematic of this study can be found in Fig. 14D. Out of 24 targets, 15 contained 
adjacent TEAD/FOXM1 binding sites, 3 contained TEAD and FOXM1 binding sites that were not 
adjacent, and 3 contained exclusively TEAD sites or FOXM1 sites (Fig. 14E). These results were 
based solely on the published ChIP-seq data from ENCODE. Expanding the search to more 
remote distances away from TSS could yield additional adjacent TEAD/FOXM1 binding sites in 
the future. These results, taken together with the IP data, suggest that a YAP/TEAD/FOXM1 
complex binding at regulatory regions of genes promoting cell growth impacts proliferation. 
FOXM1 is required for sarcomagenesis in vivo 
We evaluated the contribution of FOXM1 to sarcomagenesis in vivo using human HT-
1080 xenografts as well as a novel autochthonous murine model. Deletion of FOXM1 dramatically 
reduced tumor volume (Fig. 15A) and tumor volume (Fig. 15B) in HT-1080 xenografts. In order to 
assess the requirement for FOXM1 during sarcoma initiation and tumorigenesis in a physiological 
model that accurately recapitulates human disease, we conditionally deleted Foxm1 in our 
autochthonous KP murine system. We generated KrasG12D/+; Trp53fl/fl; Foxm1fl/fl (KPF) mice by 
crossing KrasG12D/+; Trp53fl/fl (KP) and Foxm1fl/fl animals. KPF mice developed very few tumors 
compared with KP (Fig. 15C) and the tumors that did form were significantly smaller (Fig. 15D,E). 
Of note, KP tumors contained a heterogeneous population of multinucleated, irregular, enlarged 
tumor cells compared with KPF tumors, suggesting the Foxm1-deleted tumors may undergo less 
proliferation-associated damage to the genome and accumulate fewer mutations (Fig. 15F).  We 
confirmed recombination at the Foxm1 locus in KPF tumors (Fig. 15G), which was consistent with 
IHC showing loss of Foxm1 protein levels in KPF tumors (Fig. 15H).  We also showed that YAP 
and TEAD1 are expressed in the nucleus of KP tumors, indicating that the Hippo pathway may be 
inactive in this model (Fig. 16). The lack of FOXM1 expression in the existing KPF tumors 
suggests that Foxm1 may not be required for tumor initiation in this model, but is necessary for  
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Figure 15. FOXM1 is required for sarcomagenesis in vivo. A) FOXM1 was depleted in HT-
1080 cells and 1X106 cells were injected subcutaneously in a xenograft model. Knockdown of 
FOXM1 significantly inhibited tumor growth n= 5 mice per group, P=0.04. B) Tumor weight from 
xenografts in (A) was also decreased in FOXM1-depleted cells P=0.0091. C) Autochthonous 
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mouse model of UPS, KrasG12D/+; Trp53fl/fl (KP) was crossed with Foxm1fl/fl mice to create 
KrasG12D/+; Trp53fl/fl; Foxm1fl/fl (KPF). Deletion of Foxm1 inhibited sarcomagenesis n= 10 (KP); 
n=115 (KPF). P=0.0091. D) Tumor weight was significantly decreased in KPF tumors compared 
with KP P=0.0002. E) Images of KP and KPF tumor bearing mice. F) H&E images from KP and 
KPF tumors showing the prevalence of irregular and heterogeneous tumor cells in the KP animals 
as well as the less of necrotic and stromal compartments due to Foxm1 deletion. Scale bar=100 
µM. G) Genotyping of KP and KPF animals and tumors showing recombination at the Foxm1 
locus in KPF tumors. H) IHC of Foxm1 and H&E in KP and KPF tumors showing that Foxm1 
protein expression is lost in the small KPF tumors. Scale bar=100 µM. Karin Eisinger contributed 
this figure. 
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Figure 16. YAP and TEAD1 are expressed in the nucleus of KP tumors. Tumors were 
embedded in paraffin, sectioned, and stained for YAP and TEAD1. Scale bar=50 µM. 
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tumor growth and progression. Together, these data clearly indicate that FOXM1 promotes 
sarcomagenesis, making it an attractive target for therapeutic intervention in STS. 
FOXM1 pharmacological inhibition decreases cell proliferation and tumor formation 
 To investigate the potential of FOXM1 as an STS therapeutic target, we employed a 
previously described inhibitor of FOXM1 expression, Thiostrepton (Bhat et al., 2009). 
Thiostrepton is a proteasomal inhibitor that has been shown to decrease FOXM1 protein 
expression in multiple cancer cell types (Bhat et al., 2009; Halasi and Gartel, 2009). We found 
that Thiostrepton is indeed an effective inhibitor of FOXM1 protein accumulation (Fig. 17A) while 
having no effect on FOXM1 mRNA levels, compared to shRNA (Fig. 17B). These findings are 
consistent with previous studies utilizing Thiostrepton. Of note, we successfully decreased 
FOXM1 expressing using 1 µM Thiostrepton, whereas in a breast cancer model 10 µM 
Thiostrepton was required to achieve similar levels of inhibition (Wang and Gartel, 2011), 
suggesting that sarcoma cells may be particularly sensitive to Thiostrepton.  FOXM1 inhibition 
significantly decreased sarcoma cell proliferation in vitro (Fig. 17C,D), consistent with results 
obtained using FOXM1 shRNA (Fig. 13C). Thiostrepton treatment (48 hours) also inhibited many 
of the same targets transcriptional targets sensitive to VP treatment, including Tacc3, Lox, Cdkn3, 
and Plk1 (Fig. 6E,F). These findings suggest that YAP inhibition via VP, and FOXM1 inhibition 
through Thiostrepton has similar effects on transcriptional output in sarcoma cells. To determine if 
FOXM1 could be an effective therapeutic target we performed in vivo studies using lipid 
encapsulated Thiostrepton micelles. Lipid encapsulation, as previously described (Wang and 
Gartel, 2011), allows for enhanced solubility and delivery of Thiostrepton. We treated nude mice 
bearing KP allograft tumors with vehicle control, 7.5 mg/kg or 15 mg/kg micelle-encapsulated 
Thiostrepton retro-orbitally every third day for 2.5 weeks. The higher of the two Thiostrepton 
doses significantly decreased tumor volume (Fig. 18A) and weight (Fig. 18B) while having no 
effect on overall animal health and activity. Loss of FOXM1 reduced proliferation (Ki67 IHC) (Fig. 
18C,D), consistent with loss of proliferation in YAP and FOXM1 silenced tumors. Together, these  
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Figure 17. Thiostrepton-mediated FOXM1 inhibition decreases proliferation in vitro. A) 
Immunoblot of FOXM1 levels in KIA, KP and HT-1080 cells upon 48 hours of 1µM Thiostrepton 
(Thio) or DMSO control (-). B) Foxm1 mRNA levels in KIA cells infected with scramble (Scr) or 
FOXM1 shRNA and KIA, KP and HT-1080 cells treated with Control DMSO or 1 µM Thiostrepton. 
FOXM1 mRNA is decreased upon shRNA infection but unchanged with Thiostrepton treatment. * 
P-value = 0.0134. C) Proliferation analysis of HT-1080 cells (red lines) treated with DMSO control 
or 2 µM Thiostrepton and KP cells (blue lines) treated with DMSO control or 1µM Thiostrepton. P-
value = 0.0007 for HT-1080 cells; P-value < 3.57x10-5 for KP cells. D) Proliferation analysis of KIA 
cells treated with DMSO control or 2 µM Thiostrepton. P-value = 0.0009. E) mRNA levels of 
Foxm1 targets after 24 and 48 hours of control DMSO and 1 µM Thiostrepton treatment. KP cells 
treated with 1 µM Thiostrepton showed decreases in Foxm1 target mRNA expression including 
TACC3 (P = 0.010), LOX (P = 0.032), CDKN3 (P = 0.023 at 24 hours, P = 0.0075 at 48 hours), 
VEGFA (P = 0.030), PLK1 (P = 0.00133). F) KIA cells were treated with 1µM Thiostrepton for 24 
or 48 hours.  FOXM1 transcriptional targets decreased include Tacc3 P=.0007; Myc P=.023; Lox 
P=0.020; Cdkn3 P=0.001; Vegfa P=0.019; and Plk1 P=0.002. Kevin Biju and Karin Eisinger 
contributed to this figure. 
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Figure 18. Thiostrepton-mediated FOXM1 inhibition decreases proliferation in vivo. A) 
Tumor volume in a subcutaneous xenograft of KP cells treated with PBS control and 7.5 mg/kg or 
15 mg/kg micelle-encapsulated Thiostrepton. n = 9 mice for control tumors; n = 2 mice for 7.5 
mg/kg treatment; n = 7 mice for 15 mg/kg treatment. B) Tumor weights of KP xenografts from 
micelle-encapsulated Thiostrepton treatment in A). 15 mg/kg Thiostrepton treatment resulted in 
significant decrease in tumor weight compared to control treated xenografts (P = 0.0083). C) 
Immunohistochemical staining for FOXM1 and Ki67 in control and Thiostrepton (15 mg/kg) 
treated tumors from A) at day 18. D) Quantification of Ki67 positive cells in control and 
Thiostrepton (15 mg/kg) treated tumors P=2.5X10-22. Scale bar=100 µM. Karin Eisinger and 
Kevin Biju contributed to this figure.  
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data indicate that FOXM1 inhibitors may be valuable tools for the treatment of sarcomas.  
Discussion  
The Hippo pathway has been extensively studied both during development and in 
epithelial tumorigenesis. Substantially less is known about the role of Hippo and its downstream 
effector YAP in mesenchymal tumors. Previous studies evaluating the role of YAP in STS have 
focused on alvelolar and embryonal rhabdomyosarcoma (aRMS and eRMS), two rare STS 
subtypes that affect children and adolescents (Parham and Ellison, 2006). Compared to many 
other STS, aRMS and eRMS are relatively well understood: their tissue of origin is known to be 
skeletal muscle, and for aRMS, the underlying oncogenic chromosomal translocation has been 
identified (e.g. PAX7/FOXO1), and histologically they appear less pleomorphic in comparison to 
the more aggressive, molecularly complex subtypes discussed here, including UPS, 
fibrosarcoma, and de-differentiated liposarcoma. We investigated the expression of key upstream 
Hippo pathway modulators like NF2, SAV1, MST1/2, and LATS1/2 in sarcoma patient samples 
and found that several genomic loci encoding essential factors are at least partially lost in STS. 
While it is currently unclear whether or not these genes are completely or partially deleted, we 
have shown that YAP expression and nuclear localization is stabilized in human UPS and an 
autochthonous mouse model of UPS. YAP activation is known to promote tumor growth via 
increased transcription of pro-proliferative and anti-apoptotic factors, as a TEAD cofactor. 
Moreover, YAP/TEAD – mediated FOXM1 expression is crucial for this process. However, over-
expression does not guarantee that FOXM1 is transcriptionally active in sarcomas. FOXM1 
activation is controlled by oncogenic stimuli (i.e. Ras) and loss of tumor suppressors (i.e. p53, Arf) 
(Wierstra, 2013). Perturbation of the Mitogen-activated protein kinase (MAPK) pathway and loss 
of p53 are commonly observed in sarcomas (Sasaki et al., 2011; Taylor et al., 2011). Therefore, 
the KP mouse model of UPS is an appropriate system to query the function and regulation of 
FOXM1 in STS. Conditional Foxm1 deletion in the KP model dramatically reduces tumor burden, 
suggesting that FOXM1 serves as a transcriptional node connecting Hippo pathway inactivation 
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with oncogenic stimuli/tumor suppressor loss in sarcoma (Fig.19). Furthermore, we observed that 
FOXM1 functions not only downstream of YAP, but can also interact directly with the YAP/TEAD 
complex to facilitate proliferation (Fig.19).  Together these findings suggest that inhibiting the 
YAP/TEAD1/FOXM1 complex is an attractive avenue for therapeutic intervention in these 
mesenchymal tumors. 
Pharmacologic inhibition of transcription factor/coactivator complexes has been a 
challenge due to a lack of druggable pockets in DNA-transcription factor binding. However, 
several proof-of concept small molecules and peptides have been shown to inhibit FOXM1 or 
YAP. Due to biologic inhibition by ARF, FOXM1 can be inhibited by a small synthetic ARF peptide 
(Gusarova et al., 2007). Additionally, FOXM1 can be inhibited by a class of thiopeptide antibiotics, 
including Thiostrepton. Thiostrepton efficacy against FOXM1 has been shown both in vitro and in 
vivo (Wang and Gartel, 2011). While less is known about small molecules effective at inhibiting 
YAP or TEAD, a 2012 screen for molecules disrupting the YAP/TEAD complex yielded the 
benzophyrin class of molecules as promising inhibitors. Among these, Verteporfin (VP) was 
shown to inhibit YAP/TEAD function both in vitro and in vivo, possibly by binding YAP and 
changing its structure so as to inhibit YAP/TEAD direct association (Liu-Chittenden et al., 2012).  
Currently there are no anti-cancer treatments specifically targeting YAP or FOXM1 in the 
clinic. VP is being used to treat macular degeneration under the trade name Visudyne™, but the 
mechanism of action involves generation of reactive oxygen species (ROS) for photodynamic 
therapy (Michels and Schmidt-Erfurth, 2001) rather than YAP inhibition. It may be worthwhile to 
investigate the use of VP, or related benzophyrin molecules, in YAP-driven tumors. However, it is 
generally accepted that inhibition of a major upstream regulator can have a variety of unrelated 
targets and undesired outcomes leading to cytotoxicity and patient side effects.  Therefore, we 
focused on inhibition of an essential downstream target that controls many YAP-dependent 
phenotypes, FOXM1. Thiostrepton successfully inhibited FOXM1 and reduced tumorigenesis, in 
an allograft sarcoma model, even at a relatively low dose of 15 mg/kg.  This result shows that 
FOXM1 inhibition is a promising approach for sarcoma treatment, warranting further study and 
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preclinical assessment. While Thiostrepton is not specific for FOXM1, our findings suggest that 
an unbiased screen to identify more selective inhibitors would expand therapeutic opportunities 
for sarcoma. Previous studies have shown that injection of cell permeable Arf peptides can 
effectively inhibit FOXM1 and tumorigenesis in a model of HCC (Gusarova et al., 2007). 
Targeting these peptides for delivery to sarcoma cells may also be an effective, additional 
therapeutic approach.  
One limitation of the current study is that primary sarcomagenesis, investigated in this 
study, is seldom responsible for poor patient outcome as is the case for a variety of cancers. In 
many, if not most, sarcoma cases metastatic disease burden is the principal cause of mortality. 
Importantly, sarcoma metastasis is directly linked to primary tumor hyperproliferation and 
resulting changes in intratumoral microenvironments (Eisinger-Mathason et al., 2013). While 
targeting the primary tumor should prevent metastatic progression in those patients diagnosed 
prior to micrometastatic dissemination, metastatic cells arising from YAP-driven FOXM1 
expressing sarcomas may also be sensitive to inhibition of this pathway.  Further analysis of 
metastatic tissue is required to determine if metastatic cells rely on YAP/FOXM1 to assess 
whether inhibition of this complex would target both the primary and metastatic tumor sites. Of 
note, it has been shown that YAP and FOXM1 play a role in migration/invasion and metastasis in 
other contexts (Lamar et al., 2012; Lok et al., 2011; Mo et al., 2012). Importantly, human FOXM1 
has been associated specifically with UPS metastasis (Mito et al., 2009). Further study would 
determine if YAP and FOXM1 co-regulate metastatic progression beyond their control of 
proliferation in the primary tumor. 
  Although sarcomas comprise a heterogeneous and histopathologically diverse set of 
malignancies, our work indicates that one frequently occurring genetic alteration in a subset of 
these tumor types is in the Hippo pathway. We have found that this pathway is inactivated in 
nearly half of reported sarcomas in the TCGA database, spanning diverse STS tumors. In parallel 
we have observed that FOXM1 expression is elevated in multiple STS subtypes including, de-
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differentiated liposarcoma, fibrosarcoma, leiomyosarcoma, and UPS, suggesting that some 
mechanisms may cross histological classifications. However, this finding cannot be universally 
applied to sarcoma. For example synovial sarcoma patient samples express heterogeneous 
levels of FOXM1. Together our data lead us to conclude that sarcoma classification based on 
molecular signatures, rather than solely on histopathology, would allow the development of 
therapeutics (i.e. FOXM1 inhibitors) that benefit the broadest possible, yet most accurate, cohort 
of patients.  
  
54 
 
 
 
Figure 19. Model depicting the mechanism governing YAP-mediated control of FOXM1 and 
other pro-proliferation downstream targets. 
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CHAPTER 3 
MiR-124 counteracts pro-survival stress responses in glioblastoma 
 
This chapter has been adapted from the following published paper: “MicroRNA-124 expression 
counteracts pro-survival stress responses in glioblastoma.” Mucaj V, Lee SS, Skuli N, 
Giannoukos DN, Qiu B, Eisinger-Mathason TS, Nakazawa MS, Shay JE, Gopal PP, Venneti S, 
Lal P, Minn AJ, Simon MC, Mathew LK. Oncogene, 2014 PMID: 24954504 
 
SUMMARY 
Glioblastomas are aggressive adult brain tumors, characterized by inadequately 
organized vasculature and consequent nutrient and oxygen (O2)-depleted areas. Adaptation to 
low nutrients and hypoxia supports glioblastoma cell survival, progression, and therapeutic 
resistance. However, specific mechanisms promoting cellular survival under nutrient and O2 
deprivation remain incompletely understood. In this chapter, I show that miR-124 expression is 
negatively correlated with a hypoxic gene signature in glioblastoma patient samples, suggesting 
that low miR-124 levels contribute to pro-survival adaptive pathways in this disease. Since miR-
124 expression is repressed in various cancers (including glioblastoma), we quantified miR-124 
abundance in normoxic and hypoxic regions in glioblastoma patient tissue, and investigated 
whether ectopic miR-124 expression compromises cell survival during tumor ischemia. Our 
results indicate that miR-124 levels are further diminished in hypoxic/ischemic regions within 
individual glioblastoma patient samples, compared to regions replete in O2 and nutrients. 
Importantly, we also show that increased miR-124 expression affects the ability of tumor cells to 
survive under O2 and/or nutrient deprivation. Moreover, miR-124 re-expression increases cell 
death in vivo, and enhances the survival of mice bearing intracranial xenograft tumors. miR-124 
exerts this phenotype in part by directly regulating TEAD1, MAPK14/p38α and SERP1, factors 
involved in cell proliferation and survival under stress. Collectively, among the many pro-
tumorigenic properties of miR-124 repression in glioblastoma, we delineated a novel role in 
promoting tumor cell survival under stressful microenvironments, thereby supporting tumor 
progression. 
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INTRODUCTION 
 Glioblastoma Multiforme (GBM) is the most aggressive adult brain tumor. At only 12 
months, median GBM patient survival is one of the lowest for all cancers (Krex et al., 2007). The 
standard of care for GBM treatment is surgery, followed by radiation and chemotherapy (Stupp et 
al., 2005). However, glioblastomas rapidly become resistant to these therapies, thereby making 
them ineffective at significantly improving prognosis. GBM tumors are considered Grade IV (the 
most aggressive gliomas) and occur either de novo or as a progression from lower grade lesions 
(Louis et al., 2007). In both instances, the key feature of GBM, as compared with lower grade 
gliomas, is the presence of severely hypoxic/ischemic regions (Amberger-Murphy, 2009). Low 
oxygen tension (hypoxia) is defined as less than 2% O2 and occurs in most solid tumors due to 
rapid proliferation, or aberrant angiogenesis, resulting in poor perfusion. The presence of 
hypoxic/ischemic areas is detrimental to GBM patients, as it positively correlates with recurrence 
and negatively correlates with patient survival (Evans et al., 2010; Spence et al., 2008). 
Therefore, identifying factors mediating cellular adaptation to nutrient deprivation and hypoxia is 
crucial for improving therapeutic approaches to GBM.  
 Recent studies, such as the Cancer Genome Atlas (TCGA), have elucidated genetic 
aberrations associated with glioblastomas. In addition to deregulated oncoproteins and tumor 
suppressors (such as EGFR, PDGFR, PI3K, PTEN, NF1, etc.) (2008; Verhaak et al., 2010), 
numerous micro-RNAs (miRNAs) are differentially expressed in GBMs relative to adjacent non-
neoplastic tissue (Silber et al., 2008a; Wu et al., 2012). miRNAs are ~22 nucleotide small RNAs 
that function as post-transcriptional negative regulators of ~30% of all mammalian genes 
(Ambros, 2004; Bartel, 2009). While the inhibition of any single miRNA target is relatively modest, 
each miRNA impacts the expression of numerous genes. Thus, by targeting genes involved in 
multiple pathways, a single miRNA can significantly influence systems involved in cell cycle 
progression, differentiation, and cell death, as well as broad responses to stress (Esquela-
Kerscher and Slack, 2006a). 
57 
 
 Previous studies have measured miRNA levels in glioblastoma and compared them to 
adjacent non-neoplastic tissues, or to lower-grade gliomas. In particular, miR-124 levels were 
shown to be significantly reduced in glioblastomas as compared to both adjacent non-neoplastic 
tissues (Silber et al., 2008a) and lower-grade tumors (Ben-Hamo and Efroni, 2011; Koivunen et 
al., 2012). miR-124 is a brain-enriched miRNA critical for regulating neuronal differentiation (Gao, 
2010; Lim et al., 2005; Makeyev et al., 2007b; Visvanathan et al., 2007; Yoo et al., 2011). As 
miR-124 levels are differentially expressed in distinct brain cell types, low miR-124 levels in 
glioblastoma may be a result of the cellular heterogeneity between glioma and adjacent tissue 
(Nelson et al., 2006; Sonntag et al., 2012). Alternatively, it is possible that miR-124 functions as a 
tumor suppressor in GBM. This has been suggested in the context of other tumors 
(Hatziapostolou et al., 2011; Hunt et al., 2011; Wu et al., 2012) and the abundance of known miR-
124 targets negatively correlates with miR-124 levels in brain tumor patient samples (Koivunen et 
al., 2012; Sonntag et al., 2012), leaving open the possibility that glioblastoma cells expressing low 
miR-124 levels exhibit a selective growth or survival advantage. 
 Hypoxic glioblastoma cells are often found in perinecrotic areas, where surviving cells 
experience low levels of O2 in addition to diminished nutrient and growth factor availability (Rong 
et al., 2006). Such cells must therefore adapt to steep O2 and nutrient gradients, and these 
adaptive responses are partly mediated by the Hypoxia Inducible Factors (HIFs) (Kaelin and 
Ratcliffe, 2008). Recent studies have shown that miRNAs also play a key role in modulating 
cellular survival or death under limiting O2 and nutrient availability. For example, miR-210 is 
elevated in hypoxic regions and promotes survival under low O2 (Huang et al., 2009). 
Additionally, we have shown that restoring miR-218 levels in glioblastoma opposes a Receptor-
Tyrosine Kinase/HIF signaling pathway necessary for glioblastoma progression, particularly in the 
Mesenchymal subtype (Mathew et al., 2014b).   
 Here, we show that miR-124 levels inversely correlate with a hypoxic signature in TCGA 
patient samples. Moreover, miR-124 levels are diminished in pseudopalisading regions within 
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individual glioblastoma patient tissues, when compared to relatively well-perfused regions. We 
demonstrate that increased miR-124 expression in glioblastoma cells experiencing nutrient and 
O2 deprivation promotes cell death, suggesting that miR-124 targets factors important for 
glioblastoma survival under stressful microenvironments. Moreover, miR-124 expression leads to 
increased cell death in vivo, in a doxycycline-induced tumor xenograft model that faithfully 
recapitulates hypoxic/ischemic regions in GBM. We identify three factors, TEAD1, p38α 
(MAPK14) and SERP1, as direct miR-124 targets, and show that they are overexpressed in 
hypoxic/ischemic conditions. Combined inhibition of these targets recapitulates the increased cell 
death observed under low nutrient/O2 stress, upon miR-124 expression. In addition, SERP1 re-
expression reverses the miR-124 cell death phenotype in glioblastoma cells grown under 
hypoxia. Finally, we show that miR-124 restoration confers increased mouse overall survival in an 
intracranial orthotopic xenograft model. These data suggest further investigation of miR-124 and 
its targets, in particular SERP1, is strongly warranted. 
MATERIALS AND METHODS 
Cell Culture conditions, reagents, and lentiviral transduction 
U87MG, U373, LN18 and HEK 293T cells were obtained from ATCC (Manassas, VA, 
USA), and cultured in DMEM containing 10% FBS, glutamine, non-essential amino-acids, 
Penicillin/Streptomyicin antibiotics and HEPES buffer, and passaged on average every three 
days. Cells cultured in the nutrient deprived media were grown in glucose-free DMEM containing 
glutamine, non-essential amino-acids, antibiotics and HEPES buffer, without the addition of FBS. 
Cells were grown under hypoxic incubation in a Ruskinn invivO2 400 workstation. Patient-derived 
glioblastoma tumor spheres were a gift from Dr. Jeremy Rich (Cleveland Clinic, Cleveland, OH, 
USA). These cells were maintained in Neurobasal medium, supplemented 1:50 with B27 
(Invitrogen, Carlsbad, CA, USA), Epidermal Growth Factor (Sigma, St. Louis, MO, USA) at 20 
ng/mL, and basic Fibroblast Growth Factor at 20 ng/mL. Non-targeting and miR-124 mimics were 
obtained from Dharmacon (Lafayette, CO, USA). microRNA mimic transfection was performed 
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using HiPerFect transfection reagent (Qiagen, Germantown, MD, USA). 100 mM miRNA mimics 
were used for all experiments. Tunicamycin (Sigma) was diluted in DMSO was administered at 1 
µg/mL for 24 hours. All viruses were packaged using the third generation lentivector system 
(Invitrogen) and expressed in HEK 293T cells. Supernatant containing virus was collected at 24 
hr and 48 hr timepoints and concentrated using 10-kDa Amicon Ultra-15 centrifugal filter units 
(Millipore, Billerica, MA, USA). Overexpression of SERP1 Open Reading Frame was achieved by 
cloning into the pCDH-CMV-MCS-EF1-Puro vector (Systems Biosciences, Mountain View, CA, 
USA) via EcoRI and NotI restriction sites.  
Immunoblots 
 Lysates were collected using a whole cell elution buffer previously described. 20 or 40 µg 
protein was loaded in 12% or 15% SDS-PAGE gels, transferred to nitrocellulose and blotted with 
various antibodies for TEAD1 (Novus, St. Charles, MI, USA), p38α (Cell Signaling, Danvers, MA, 
USA), SERP1 (Genetex, Irvine, CA, USA), β-tubulin, PARP, cleaved PARP, (Cell Signaling). 
Primary antibodies were diluted 1:1000 in 5% non-fat milk TBST.  
Cell death assays 
 Cell death was assessed using Annexin-PI staining on Flow Cytometry, using the FITC 
Annexin V Apoptosis Detection Kit I from BD Pharmingen (San Jose, CA, USA). For nutrient 
deprivation/hypoxia experiments, cells were kept under stress conditions for 48 hours before cell 
death was assayed. For tunicamycin experiments, cells were kept under stress conditions for 24 
hours.  
In vivo xenograft assays 
 All experiments were performed in accordance with NIH guidelines and approved by the 
University of Pennsylvania Institutional Animal Care and Use Committee (IACUC). Sub-
cutaneous xenografts were performed on Nu/Nu mice (Charles River, Burlington, MA, USA) as 
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previously described. 1,000,000 U87-MG cells expressing the empty pCDH-EF1-copGFP 
lentivector or the pCDH-EF1-copGFP-pre-miR-124 lentivector were injected on flanks of nude 
mice and the tumors were subsequently measured by caliper over the period of a month. 
Additionally, sub-cutaneous xenografts were performed with U87-MG cells expressing: Scr 
shRNA, TEAD1 shRNA, SERP1 shRNA, doxycycline-inducible miR-124 and doxycycline 
inducible control. Tumor volume was measured using the calculation: (X•Y2)π/6, where X is the 
longest caliper measurement, Y is the shortest, and π=3.14. For the doxycycline-inducible 
experiments, mice were fed 2 mg/mL doxycycline and 5% glucose in their drinking water for 7 
days.  
 Orthotopic xenograft injections were performed by stereotactically injecting 500,000 U87-
MG glioblastoma cells in 5 uL PBS, 5mm in the right cerebral hemisphere in 8-week-old Nu/Nu 
mice. As in the sub-cutaneous xenograft experiment, the U87-MG cells were expressing either 
the empty pCDH-EF1-copGFP, or the pCDH-EF1-copGFP-pre-miR-124 lentivector. Prior to 
injection, the mouse was prepared as previously described. The animals were sacrificed at the 
first sign of neurological symptoms. 
Immunohistochemistry (IHC) and Immunofluorescence (IF) assays 
IHC and IF were performed on 5 µm sections according to standard protocols. Antibody 
concentrations are the following: HIF1α: 1:100 (Abcam, Cambridge, UK), GFP: 1:100 (Cell 
Signaling). Images were taken using a Leica 500 microscope (Leica, Solms, Germany) at 10X 
magnification. Paraffin embedded sections were stained for TUNEL using an ApopTag Plus 
Fluorescein In situ Apoptosis Detection Kit (Chemicon, Temecula, CA, USA) according to the 
manufacturer’s instructions. Images were taken at 20X magnification using an Olympus IX81 
microscope (Olympus, Center Valley, PA, USA).  
Laser Capture Microdissection 
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FFPE slides were lightly stained with Hematoxylin and Eosin and immediately subjected 
to laser capture under RNase-Free conditions. For pseudopalisading regions, the internal necrotic 
core was initially cut and discarded, before the pseudopalisading region was collected for testing. 
Microdissection was performed using a Leica microscope and the Leica LMD software. Upon 
collection, RNA was extracted using the Qiagen miRNeasy FFPE kit.  
Patient samples 
 LCM tissue: At the Hospital of the University of Pennsylvania, we searched the 
departmental surgical pathology database for cases with the diagnosis of "Glioblastoma, WHO 
grade IV" over a two year period (2011-2013). Only primary glioblastomas that had not received 
prior radiation or chemotherapy were included. Subsequently, the cases were screened by a 
neuropathologist (P.P.G) for adequate areas of both pseudopalisading necrosis and solid tumor, 
and whether it was possible to obtain ten 10 um unstained tissue sections from the archived 
paraffin embedded formalin fixed tissue blocks. mRNA extraction from whole patient sample: the 
formalin-fixed, paraffin-embedded (FFPE) patient samples were obtained from the University of 
Pennsylvania Department of Pathology and Laboratory Medicine (Philadelphia, PA). GBM blocks 
were screened by a neuropathologist (S.V) contained > 95% tumor cells. Controls (temporal 
lobectomy tissue obtained from intractable epilepsy patients) showed histopathologic evidence of 
mild to focally moderate gliosis, but no lesions. GBM patients age range: 24 to 89 years, (Median: 
63 years). Control patients age range: 22 to 61 years, (Median: 38 years). RNA was obtained 
from FFPE samples using the RecoverAll™ Total Nucleic Acid Isolation kit (Ambion, Austin, TX, 
USA).  
Bioinformatic analyses 
 mRNA expression data were downloaded from the TCGA Data Portal (https://tcga-
data.nci.nih.gov/tcga/). Data generated on the Affymetrix microarray platform HT_HG-U133A for 
385 tumor and 10 normal samples was subjected to GCRMA normalization (GCRMA background 
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correction, quantile normalization, log2 transformation and Median polish probeset 
summarization) was used to determine mRNA expression. To obtain expression, previously 
normalized TCGA Level2 data from 426 tumor samples and 10 normal samples run on Agilent’s 
miRNA microarray was utilized. Data were analyzed using the Partek software (Partek Inc., St. 
Louis, MO, USA). To determine the association between miR-124 and expression of the HIF 
signature, we utilized the Gene Set Analysis (GSA) implementation (version 1.03) of Gene Set 
Enrichment Analysis (GSEA). We defined the HIF signature by using previously - established HIF 
regulated genes (Koivunen et al., 2012). To create a single value that represents the expression 
of the HIF signature (HIF metagene), the average expression of all the genes in the HIF signature 
was calculated for each tumor sample (using TCGA GBM data). This HIF metagene was then 
used as a continuous variable for various comparisons between groups. Analysis was performed 
using the R language and environment for statistical computing. 
Statistics 
 All statistical analysis was performed using the GraphPad Prism™software (La Jolla, CA, 
USA). All data are represented as mean ± S.E.M. To establish whether a difference between two 
values is statistically significant, we performed Student’s t-test, where p < 0.05 defines statistical 
significance. 
RESULTS 
miR-124 levels inversely correlate with hypoxia signatures in glioblastoma patients and are 
further decreased in pseudopalisading necrotic regions within patient tissues.  
 While several studies have shown that miR-124 levels are low in glioblastomas as 
compared to adjacent non-neoplastic tissues, little is known about how miR-124 levels correlate 
with low O2 microenvironments. We took advantage of the large TCGA glioblastoma dataset 
(2008), and compared miR-124 levels to a “hypoxia” signature identified in the GBM patients’ 
expression profile. We defined a Hypoxia Inducible Factor (HIF) metagene by averaging the 
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expression of known HIF-regulated genes (Koivunen et al., 2012) from each TCGA patient into a 
single expression value. A high HIF metagene score positively correlates with high levels of 
hypoxia in each patient sample. Interestingly, miR-124 levels negatively correlated with the HIF 
metagene, suggesting that GBM tissues experiencing highly hypoxic microenvironments have 
even lower miR-124 levels (Fig. 20A, Fig. 21). Furthermore, we stratified TCGA patients based on 
miR-124 levels (high vs. low) and observed that patients expressing the lowest levels of miR-124 
exhibited a higher correlation with the HIF metagene. To validate our analysis, we also queried 
the levels of miR-210, a known miRNA stimulated by hypoxia, which positively correlated with the 
HIF metagene (Fig. 20B).  
 While the TCGA contains a large repository of patient samples, it does not compare 
normoxic and hypoxic regions of glioblastoma within the same tumor. To determine whether miR-
124 levels were changing in hypoxic/ischemic domains within an individual glioblastoma patient 
sample, we performed laser-capture microdissection, collected regions of pseudopalisading 
necrosis, and compared them to non-necrotic, better-perfused areas. (Fig. 22A,B). We compared 
miR-124 and GLUT1 levels between the perfused (“normoxic”) and hypoxic regions of each 
individual patient, and showed that, while miR-124 levels are already low in glioblastoma tissue, 
they are further diminished in domains experiencing hypoxia/ischemia (Fig. 22C, left panel). 
Conversely, GLUT1, a hypoxically induced HIF target gene, was elevated in the hypoxic regions 
(Fig. 22C, right panel). Taken together, these findings suggest the possibility that miR-124 levels 
may be further decreased in hypoxic/ischemic domains, potentially to confer a survival advantage 
within a stressful microenvironment.  
miR-124 expression increases cell death in glioblastoma cells grown under limiting nutrients and 
oxygen. 
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Figure 20. Correlation between miRNA levels and hypoxic metagene in TCGA patient 
samples. A) Hypoxia Inducible Factor (HIF) metagene correlation to miRNA levels. MiRNAs that 
are positively and negatively correlated with the metagene are indicated blue = p - value < 0.05. 
Red dot = miR-124. B) HIF metagene in TCGA GBM patient samples divided into high and low 
miR-124 / miR-210 levels. Andy Minn assisted with the completion of this figure. 
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Figure 21. Correlation between miR-124 levels and individual hypoxia/HIF signature 
targets.   Gene Set Enrichment Analysis showing a negative correlation between a hypoxic gene 
signature and miR-124 levels. Red dots = miR-124 levels for each individual TCGA patient (log  
scale). Heatmap shows individual levels of each patient sample.  Orange = high level of mRNA 
expression. Blue = low level of mRNA expression. Andy Minn assisted with the completion of this 
figure. 
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Figure 22. miR-124 is decreased in pseudopalisading regions within patient tumors. A) 
Schematic of Laser-Capture Microdissection. Left: region of pseudopalisading necrosis. The inner 
necrotic region is discarded, while the pseudopalisade is collected as “hypoxic tissue”. Right: 
Non-necrotic region, collected as the perfused (“normoxic”) tissue counterpart. B) Laser-Capture 
microdissection images before and after microdissection. Red line indicates necrotic sample that 
was discarded as waste. Green line indicates perinecrotic area that was collected after disposal 
of necrotic sample. C) miR-124 and GLUT1 mRNA levels in perfused or “normoxic” and hypoxic 
regions in patient samples. Top: averages; bottom: paired representation (each pair is from an 
individual patient). * p - value = 0.047 (miR-124 changes); p - value = 0.035 (GLUT1 changes). n 
= 4 patients. 
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 To determine whether miR-124 levels affect glioblastoma cells during stress, we 
increased miR-124 expression in U87MG and LN18 glioblastoma cells and incubated them for 48 
hours under nutrient deprivation (no glucose, no serum) or hypoxia (0.5% O2). Interestingly, we 
found that miR-124 re-expression resulted in a significant increase in cell death in glioblastoma 
cells cultured under nutrient or O2 deprivation, as measured by Annexin/PI staining and flow 
cytometry (Fig. 23A,C). Consequently, a slight increase in cleaved PARP accumulation was 
observed (Fig. 23B). As shown previously, no significant change in cell viability was observed in 
glioblastoma cells grown under replete O2 and nutrients upon miR-124 expression (Fig. 23A), 
suggesting that cell death is due to miR-124 negatively regulating factors responsible for pro-
survival, adaptive responses specifically during stress. We confirmed these results by modulating 
serum and O2 levels in U373-MG cells and imaging miR-124-dependent cell death (Fig. 24). Of 
note, miR-124 enhanced cell death was also observed when cells were treated with tunicamycin, 
a small molecule that induces ER stress (Fig. 23D-F). Based on these results, we hypothesized 
that miR-124 may be targeting factors that are active under stress conditions, and subsequently 
their pro-survival effects. 
TEAD1, MAPK14/p38α, and SERP1 are miR-124 direct targets.  
 To identify potential miR-124 targets promoting survival during stress, we queried various 
miRNA target prediction bioinformatic databases, including TargetScan™, miRBase™ and 
DIANA-LAB, as well as previously published microarrays of genes modulated by miR-124 
overexpression (Lim et al., 2005; Makeyev et al., 2007b), and identified three putative miR-124 
targets that may play a role in pro-survival stress responses: MAPK14/p38α, TEAD1 and SERP1.  
 TEAD1 (TEA Domain 1) is a transcription factor regulated by the Hippo pathway, which 
controls the expression of many pro-proliferation genes (Zhao et al., 2008a). Interestingly, a 
recent study has shown that TEAD1 overexpression leads to an anti-apoptotic phenotype in HeLa 
cells (Malt et al., 2012). p38α (also known as MAPK14, MAP kinase 14) is a kinase typically  
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Figure 23. miR-124 expression increases cell death in glioblastoma cells grown under 
limiting nutrients and oxygen. A) U87-MG and LN18 cells were grown under the following 
conditions: Complete Media (C.M.), Glucose/Serum-Free, and Hypoxia (0.5% O2). Cells were 
transfected with either a Non-Targeting (NT) or miR-124 mimic (miR-124) for 48 hours, followed 
by Annexin/PI staining and flow cytometry for cell death analysis. B) Immunoblots of cleaved (cl.) 
PARP in cells treated as described in (A) (lysates probed with total PARP antibody which shows 
both PARP and cleaved PARP). C) Representative Annexin – PI flow cytometry plots of U87MG 
cells corresponding to (A). D) U87-MG cells were treated with tunicamycin or DMSO control, and 
transfected with either a NT or miR-124 mimic for 24 hours, followed by Annexin/PI staining and 
cell death analysis by flow cytometry. E) Immunoblot of cleaved PARP in cells described in (D). 
F) Representative Annexin – PI flow cytometry plots from (D). * p - value < 0.05. 
  
69 
 
 
Figure 24. miR-124 elicits increased cell death under stress. Descriptive images of U373-MG 
cells transfected with NT or miR-124 mimics and grown in complete media, serum-free media, 
0.5% O2, or a combination of serum-free media and 0.5% O2 and imaged for viability. In 
particular, miR-124-treated cells grown in the Serum-Free Media + 0.5% O2 condition exhibit a 
crumpled, detached phenotype, with missing cellular protrusions (white arrows).   
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activated as a response to upstream stress signaling. Although p38α is thought to be tumor 
suppressive in some settings (Wagner and Nebreda, 2009), it may have a pro-tumorigenic role in 
GBM: an activated p38-MAPK pathway signature correlates with poor survival in glioblastoma 
(Ben-Hamo and Efroni, 2011), and increased glioblastoma invasion (Demuth et al., 2007). 
Interestingly, a recent study demonstrated that miR-124 can decrease MAPK14 levels, to 
counteract p38α signaling in neurons (Lawson et al., 2013). TEAD1 and p38α are upregulated in 
several cancers, including colon, prostate, lung and pancreatic cancer (Malt et al., 2012; Paillas 
et al., 2012), suggesting a pro-tumorigenic role for these proteins. SERP1 (stress-associated 
endoplasmic reticulum protein, also known as RAMP4) is a 7 kD peptide located within the sec61 
ER translocon protein complex. While very little is known about SERP1 biological functions, it has 
been proposed that this peptide is critical for the folding of newly synthesized proteins under 
stress conditions: SERP1 was originally identified as a peptide exhibiting increased expression 
during hypoxia and hypoglycemia (Yamaguchi et al., 1999b), and Serp1-/- mice are more 
susceptible to ER stress (Hori et al., 2006a).   
 According to TargetScan™, MAPK14 harbors a putative conserved miR-124 binding site 
in its 3’ Untranslated Region (UTR), while TEAD1 and SERP1 have two putative conserved 
binding sites each (Fig. 25A). We ectopically increased Non-Targeting (NT) and miR-124 levels in 
U87MG and LN18 cell lines, and assessed target mRNA levels by quantitative RT-PCR (Fig. 
25B) and protein levels in U87MG, U373 and LN18 cell lines by immunoblot (Fig. 25C). In all 
cases, miR-124 expression led to decreased levels of each of the three mRNA and protein 
targets, respectively. We then transduced lentiviruses expressing either a Non-Targeting or a pre-
miR-124 vector into human glioblastoma “stem like cells” grown as tumor spheres and again 
showed that miR-124 overexpression leads to decreased levels of target mRNA (Fig. 25D). To 
investigate whether MAPK14, TEAD1 and SERP1 are direct miR-124 targets, we employed a 3’ 
UTR luciferase assay comparing luciferase levels in cells transfected with plasmids expressing 
wild type 3’ UTRs or those harboring mutations in the miR-124 seed binding sites (see Table 4 
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Figure 25. TEAD1, MAPK14/p38α, and SERP1 levels decrease upon miR-124 transfection. 
A) Schematic of miR-124 seed sequence binding sites in the 3’ untranslated regions of the three 
putative targets. B) MAPK14/p38, TEAD1 and SERP1 mRNA levels in U87-MG and LN18 cells 
treated either with a Non-Targeting (NT) or a miR-124 mimic after 12 hours of transfection. C) 
p38, TEAD1 and SERP1 protein levels in U87-MG, U373-MG, and LN18 cells treated either with 
a Non-Targeting (NT) or miR-124 mimic after 72 hours of transfection. D) mRNA levels of 
glioblastoma stem like cells grown as tumor spheres transduced with either an empty control or 
pre-miR-124 expressing virus. 
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Figure 26. TEAD1, MAPK14/p38α, and SERP1 are direct miR-124 targets. T98G cells 
transfected with pMIR-REPORT with intact or mutated seed sequences were tested for luciferase 
activity in the presence of stable miR-124 expression. Luciferase levels for A) MAPK14, B) 
TEAD1 and C) SERP1 3’UTR constructs. RLU: Relative Luciferase Units. 
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Table 4. Oligonucleotide primer sequences of TEAD1, SERP1 and MAPK14 partial 3’UTRs 
containing miR-124 binding sites. WT: Wildtype. MUT: Mutated seed sequence binding site (in 
red). MAPK14 has only one miR-124 binding site, whereas TEAD1 and SERP1 have two miR-
124 biding sites each.  
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for 3’ UTR oligo sequences used). We determined that all three targets are directly regulated by 
miR-124, as luciferase levels decreased upon miR-124 expression in cells expressing the wild 
type 3’UTR regions, but not in cells expressing 3’UTR regions with mutated miR-124 seed 
sequences (Fig. 26A-C). (Note: only one SERP1 seed sequence binding [S2] site appears to be a 
bona fide miR-124 binding site [Fig. 26C]). 
TEAD1, MAPK14 and SERP1 promote glioblastoma progression. 
 To assess whether MAPK14, TEAD1, and SERP1 play a role in glioblastoma 
tumorigenesis, we obtained RNA from formalin-fixed, paraffin embedded (FFPE) glioblastoma 
patient samples, procured from the University of Pennsylvania Department of Pathology. A 
comparison of average miR-124 levels between glioblastoma RNA versus normal brain tissue 
RNA showed that miR-124 levels are greatly diminished in GBM, relative to normal brain, as 
previously shown (Silber et al., 2008a) (Fig. 27A). Of note, MAPK14, TEAD1 and SERP1 mRNA 
levels exhibited the opposite result: mRNA levels of these targets were higher in GBM samples 
compared to normal brain tissue (Fig. 27B-D). These data suggest an important role for all three 
genes in glioblastoma. In order to verify whether they promote glioblastoma cell survival, we 
employed short hairpin RNAs (shRNAs) to inhibit TEAD1, MAPK14, and SERP1 individually (Fig. 
28A; Fig. 28B shows resulting mRNA levels) and as part of a combined triple depletion (Fig. 28C; 
Fig. 28D depicts corresponding protein levels). Decreased expression of each miR-124 target 
partially enhanced cell death under nutrient or O2 deprivation (Fig. 28A); in contrast, combined 
loss of TEAD1, MAPK14 and SERP1 fully recapitulated the increased apoptosis (Fig. 28C) 
observed in miR-124 expressing cells (see Fig. 23).  
 Finally, we treated U87-MG cells with scrambled or pre-miR-124 lentivirus and subjected 
them to low O2 or serum-free/low O2 conditions for 24 hours. Upon stress, particularly the serum-
free/low O2 conditions, a marked increase in all three targets was observed (6-8 fold) (Fig. 29A-
C). miR-124 treatment counteracted this increase, bringing target levels closer to baseline. At the  
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Figure 27. miR-124 and target levels in normal brain and glioblastoma in RRFPE patient 
samples. A) miR-124, B) MAPK14, C) TEAD1, and D) SERP1 levels in GBM (n=30) and normal 
brain samples (n=10). * p value < 0.05. GBM: Glioblastoma tissue. Normal: Normal brain tissue.  
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Figure 28. TEAD1 MAPK14 and SERP1 recapitulate miR-124 cell death phenotype. A) 
shRNA-mediated inhibition of individual targets partially recapitulates the cell death phenotype 
observed in Figure 2a. * p value < 0.05. B) Transcript levels of all three targets, upon shRNA-
mediated inhibition of any single target. C) Cell death levels after shRNA-mediated depletion of all 
three targets combined (Triple KD). D) Immunoblot showing target protein levels upon triple 
ablation. Scr = Scrambled control shRNA, triple = shRNAs for all three targets. Dion Giannoukos 
assisted with the completion of this figure. 
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Figure 29. miR-124 counteracts target increase under stress. mRNA levels of A) MAPK14, B) 
TEAD1, and C) SERP1 under the following conditions: Complete Media (C.M.), Hypoxia (0.5% 
O2), and Serum Free + Hypoxia (0.5% O2). U87-MG cells were transduced with scrambled control 
(Scr) or pre-miR-124-expressing lentivirus and subjected to these conditions for 24 hours. D) 
NOXA levels from same experiment. * p - value < 0.05; ** p - value < 0.001, *** p - value < 
0.0001. 
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same time, ectopic miR-124 expression under serum-free/low O2 conditions significantly 
increased NOXA levels, a marker of apoptotic cell death (Fig. 29D).  
miR-124 expression affects glioblastoma cell proliferation and survival in vivo. 
 In order to establish a role for miR-124 re-expression/target gene downregulation in vivo, 
we transduced U87-MG cells with control or pre-miR-124 – GFP, and assessed growth both in 
vitro (cell counts) and in vivo (subcutaneous xenografts). Additionally, we performed the same 
experiments comparing non-targeting shRNA vs. TEAD1, SERP1, or MAPK14 shRNAs. As 
previously established (Silber et al., 2008a), miR-124 re-expression leads to decreased cell 
proliferation in vitro (Fig. 30A) and subcutaneous tumor growth in vivo (Fig. 30E). TEAD1 and 
MAPK14/p38α inhibition also resulted in decreased in vitro proliferation when U87-MG cells were 
grown under replete media (Fig. 30B,C). SERP1 knockdown did not result in significant 
differences in in vitro proliferation under replete media, but resulted in decreased proliferation 
when cells were grown under 0.5% O2. (Fig. 30D). TEAD1 and SERP1 inhibition led to decreased 
tumor growth in vivo (Fig. 30F,G; p38α modulation has been previously shown to lead to 
decreased tumor growth in glioblastoma growth in vivo (Cloninger et al., 2011), thus not shown 
here).  
 Since increased miR-124 expression led to a significant difference in tumor size (Fig. 
30A), it was difficult to determine whether increased cell death occurred in areas experiencing 
limited nutrient and O2 availability, since smaller tumors exhibit fewer hypoxic/ischemic regions. In 
order to mitigate this scenario, we devised a doxycycline-inducible system where miR-124 
expression is regulated by doxycycline administration. Briefly, we created stable U87-MG cell 
lines expressing either a doxycycline-inducible control or miR-124, along with GFP, to assess the 
robustness of the system. As shown in the schematic in Fig. 31A, subcutaneous tumors were 
allowed to grow for 20 days in nude mice, so that they achieved a size sufficient for the natural 
generation of O2/nutrient gradients. At day 20, doxycycline was administered, thereby activating 
expression of miR-124-GFP, or the control-GFP construct. The doxycycline-inducible system was 
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Figure 30. miR-124 and target modulation affects proliferation in vitro and in vivo. A) Cell 
count of U87-MG cells expressing miR-124 or a control scrambled miRNA. Cell count of U87-MG 
cells expressing control or B) TEAD1 shRNA, C) MAPK14 shRNA and D) SERP1 shRNA. Growth 
curves and tumor weights of subcutaneous xenografts of U87-MG cells expressing miR-124 (E, 
n=9), TEAD1 shRNA (F, n=9), and SERP1 shRNA (G, n=6). Dion Giannoukos and Michael 
Nakazawa assisted with the completion of this figure. 
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validated in vitro as described in Fig. 32A,B. Surprisingly, no statistically significant difference in 
tumor size was observed after doxycycline treatment (Fig. 31B). Subcutaneous tumor 
architecture was similar in both control and miR-124 expressing tumors, and both showed regions 
of hypoxia as demonstrated by HIF-1α staining (Fig. 31C). However, when we stained for GFP 
(the proxy for expression of either the control or the miR-124 construct), a significant loss of GFP-
expressing cells was detected in the tumor tissues expressing the miR-124 construct (Fig. 
31D,E), even though both constructs expressed GFP in a doxycycline-dependent manner in vitro 
(Fig. 32A). We then quantified cell death using the terminal deoxynucleotidyl transferase dUTP 
nick end-labeling (TUNEL) assay, and observed increased apoptosis in tissues expressing miR-
124, compared to those expressing the control construct (Fig. 31F,G). While there are many 
possible explanations for these observations, increased TUNEL staining in miR-124 expressing 
tumors, coupled with decreased numbers of GFP-expressing cells, suggest that miR-124 
expressing cells may be selected against in the seven days of doxycycline treatment, due to their 
inability to survive O2 and nutrient deprivation.  
SERP1 is an important pro-survival target in glioblastoma.  
 Since SERP1 has been shown to be elevated during brain ischemia , we focused on 
dissecting the role for SERP1 in survival under stress. We decreased SERP1 levels via an 
shRNA-mediated lentivirus in U87-MG cells and subjected them to low O2 or serum-free/low O2 
conditions for 24 hours. Just as we observed in Fig. 29C, SERP1 transcripts are elevated under 
stress (Fig. 33A). Importantly, we demonstrate that shRNA treatment recapitulates the miR-124 
phenotype by eliciting increased NOXA levels (Fig. 33B).  We therefore determined if re-
expression of the SERP1 Open Reading Frame (lacking the 3’UTR) reverses miR-124-mediated 
cell death. Increased miR-124 expression led to enhanced cell death under hypoxia, while 
SERP1 re-expression almost completely abrogated miR-124-mediated cell death under hypoxia 
(Fig. 33C). This underscores a previously unappreciated role for SERP1 in glioblastoma. As 
observed with our FFPE patient samples in Fig. 27D, TCGA patient data also  
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Figure 31. Doxycycline-Inducible xenograft assay. A) Schematic of assay. B) Growth curve of 
doxycycline inducible subcutaneous xenografts after expressing control or miR-124 for seven 
days. C) H&E and HIF-1α IHC staining of doxycycline-inducible subcutaneous xenograft tumor 
sections. Scale bar is 200 µm. (D, E) GFP IHC staining and quantification, (F, G) TUNEL staining 
and quantification of doxycycline-inducible subcutaneous xenograft tumor sections. Scale bar is 
100 µm. * p - value < 0.05. 
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Figure 32. Determination of lentiviral and doxycycline-inducible systems in vitro. A) Flow 
cytometry analysis of Green Fluorescent Protein expression in Control-Dox expressing  and 124-
Dox expressing U87-MG cells. Time lapse of doxycycline administration up to 72 hours. FSC =  
Forward Scattering; Dox = Doxycycline. B) qRT-PCR measuring miR-124 levels upon 
doxycycline induction for a 72 hour time course. Bo Qiu assisted with the completion of this 
figure. 
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Figure 33. SERP1 is an important factor in glioblastoma. A) SERP1 and B) NOXA mRNA 
levels in U87-MG cells grown under the following conditions: Complete Media (C.M.), Serum-
Free, Hypoxia (0.5% O2), and Serum Free + Hypoxia (0.5% O2). Cells were transduced with 
scrambled (Scr) or SERP1 shRNA and subjected to these conditions for 24 hours. * p - value < 
0.05; ** p - value < 0.001, C) SERP1 Open Reading Frame re-expression leads to rescue of cell 
death in U87-MG expressing miR-124 under hypoxia. D) SERP1 levels in normal brain and GBM 
tissues from the TCGA dataset (p - value < 0.0001). E) Kaplan – Meier survival curve of patients 
from the REMBRANDT database, stratified by SERP1 expression levels (p - value = 0.006).  
  
84 
 
suggest that SERP1 mRNA levels are elevated in glioblastoma samples, as compared to normal 
brain tissue (p - value < 0.0001) (Fig. 33D). Additionally, a query into the REMBRANDT database 
(https://caintegrator.nci.nih.gov/rembrandt/) showed that patients with increased SERP1 mRNA 
exhibit lower overall survival, compared to patients with low or intermediate levels (p - value = 
0.006) (Fig. 33E). Taken together, these data suggest that SERP1 may be an attractive target for 
further evaluation in glioblastoma survival.  
miR-124 expression increases overall survival in an orthotopic intracranial mouse model. 
 While several studies have investigated the role for miR-124 in glioblastoma (Li et al., 
2011; Silber et al., 2008a), the impact of miR-124 expression on glioblastoma cell survival in vivo 
is unclear. To test whether miR-124 expression led to a change in tumor cell survival, we 
performed an intracranial orthotopic experiment in Nu/Nu mice expressing either control or pre-
miR-124 construct, as well as GFP. miR-124 levels were increased only ~50 fold (data not 
shown), similar to the difference in miR-124 levels between GBM and adjacent non-neoplastic 
tissue measured in patients (Godlewski et al., 2008; Silber et al., 2008a). GFP levels were similar 
between control and miR-124 constructs (Fig. 34C). Mice were sacrificed upon showing 
neurological symptoms associated with tumor burden. We observed that miR-124 re-expression 
conferred mice with a higher survival rate (p - value < 0.0001) (Fig. 34A, 34B shows brain 
sections upon sacrifice), suggesting the importance of silencing miR-124 during GBM tumor 
progression.  
DISCUSSION 
 Glioblastomas are difficult to treat, primarily due to their resistance to standard of care 
therapy and eventual tumor recurrence. Both resistance to therapy and recurrence are closely 
associated with the frequent occurrence of hypoxic/ischemic regions in grade IV gliomas. The 
ability of glioblastoma cells to survive under nutrient and O2 deprivation ensures the opportunity 
for glioblastoma recurrence. Many factors are over - and underexpressed to promote cellular  
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Figure 34. miR-124 expression increases overall survival in an orthotopic intracranial 
mouse model. A) U87-MG cells transduced with either an empty control or pre-miR-124 
expressing virus were injected into nude mice, subsequently surveyed for survival. Kaplan-Meier 
curve, *** p - value < 0.0001. B) Representative H&E images of xenografts in the brain showing 
tumor lesions (arrows) at the time of sacrifice. C) GFP levels in control/pre-miR-124 transduced 
U87-MG cells, 48 hours after transduction.  
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Figure 35. Model for miR-124 role in glioblastoma. miR-124 loss contributes to glioblastoma 
tumorigenesis by promoting the elevated expression of cell proliferation factors, as well as pro-
survival factors, especially in regions experiencing nutrient and oxygen deprivation.  
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survival, and a majority have yet to be elucidated. Several micro-RNAs have been demonstrated 
to promote survival under stress. Here, we show that miR-124 loss in glioblastoma allows for 
survival during nutrient and O2 deprivation, as miR-124 re-expression in glioblastoma cells 
increased cell death under these conditions.  
 miRNAs function by targeting and modestly inhibiting a vast array of mRNAs and 
proteins. Given that miRNAs can inhibit up to 30% of the mammalian genome (Esquela-Kerscher 
and Slack, 2006a), differentially expressed miRNAs are a powerful discovery tool in cellular 
processes impacting development, physiology and disease. While a single miRNA inhibits any 
given mRNA or protein only ~10-20%, global pathway changes can be significant. Additionally, 
modulating miRNA levels often reveals new targets or pathways that have been under-
investigated or not well understood. Previous studies have identified an anti-proliferative role for 
miR-124 in glioblastoma (Silber et al., 2008a), but no consistent evidence has linked miR-124 to 
cell death under limiting O2 and nutrient conditions in the context of glioblastoma. A recently 
published study showed that miR-124 levels are downregulated in pulmonary artery smooth 
muscle cells (PASMC) subjected to hypoxia, implying that miR-124 expression could be utilized in 
the future to target effectors of pulmonary arterial hypertension (Kang et al., 2013). In this paper, 
we show that miR-124 levels (while decreased in glioblastoma compared to normal brain tissue) 
are further diminished in pseudopalisading necrotic/hypoxic regions as compared to better-
perfused tissue. Based on TCGA data, the more patient samples express a hypoxic signature, 
the lower miR-124 levels become. While the observation that miR-124 levels anti-correlate with 
hypoxic regions and hypoxic signatures in patients (Fig. 20) does not necessarily imply that miR-
124 has been selectively inhibited to confer survival, endogenous miR-124 expression has a 
significant effect in inhibiting cell survival in hypoxic/ischemic glioblastoma tissue.  We 
demonstrate for the first time how miR-124 controls cell death through inhibition of various pro-
survival targets elevated under low nutrients, growth factors and O2, making miR-124 an 
attractive target for further investigation in glioblastoma. Our current model suggests that, due to 
lack of miR-124 expression, tumor cells acquire the ability to uncontrollably proliferate, as these 
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cells express high levels of pro-proliferation factors including CDK-6 (Silber et al., 2008a), and 
TEAD1 (Fig. 25). During growth and expansion, glioblastoma tissues invariably experience 
gradients of nutrient and O2 availability, and in many cases, regions where nutrients and O2 are 
significantly depleted. Our study suggests that lack of miR-124 allows cells in these regions to 
upregulate pro-survival factors (such as SERP1, a novel miR-124 target). Taken together, lack of 
miR-124 expression allows glioblastoma cells to proliferate, but also survive under stress 
conditions (Fig.  35, model). While at the present time miRNA-based therapeutics await further 
development, investigating miRNA targets should lead to insights into the biological processes of 
glioblastoma, as well as potential new therapeutic modalities. 
  One interesting novel miR-124 target described here is SERP1. No previous connection 
has been made between SERP1 and glioblastoma progression, and very little is known about the 
biological roles for SERP1 in the endoplasmic reticulum. So far, SERP1 appears to have a role in 
modulating responses to ER stress (Hori et al., 2006a) and protecting proteins from degradation 
while promoting consequent glycosylation (Yamaguchi et al., 1999a). Additionally, it was shown 
that SERP1 levels are elevated in astrocytes during rat brain ischemia (Yamaguchi et al., 1999a). 
Since miR-124 re-expression led to increased cell death under tumor ischemic and ER stress 
conditions, we hypothesized that miR-124 counteracts pro-survival stress responses in 
glioblastoma, in part by targeting SERP1. Here, we identify SERP1 as an important factor in 
glioblastoma patient survival. Additionally, we show that SERP1 overexpression rescues the cell 
death phenotype conferred by miR-124, suggesting that SERP1 may provide a pro-survival 
(hence, pro-tumorigenic) role in vivo.  
 Liu et al. have recently shown that miR-124 levels decrease in the sub-ventricular zone 
when mice are subjected to cerebral ischemia, in a model of stroke (Liu et al., 2011). The authors 
suggest that decreased miR-124 allows for increased proliferation in the ischemic region during 
stroke-induced neurogenesis. We demonstrate that, in addition to allowing for cellular 
proliferation, the decrease in miR-124 may also be permissive for cellular survival during stroke, 
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potentially by allowing for SERP1 upregulation under low nutrients and O2, as described by 
Yamaguchi and colleagues (Yamaguchi et al., 1999b). Thus, more research regarding the 
connection between miR-124, SERP1, and hypoxia/ischemia is warranted, in the settings of 
stroke and glioblastoma tumorigenesis.  
 In summary, we have shown glioblastoma cells undergo apoptosis under 
hypoxic/ischemic conditions, upon miR-124 reintroduction. This increase in cell death may be 
partially mediated by direct miR-124 inhibition of TEAD1, MAPK14/p38α and SERP1, in addition 
to numerous other factors. Further research on miR-124 targets involved in survival under 
nutrient and O2 deprivation may lead to novel glioblastoma therapeutics.  
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CHAPTER 4 
Concluding Remarks 
 
 
 The previous two chapters described experiments that asked how cancer cells control 
proliferation and survival under stress, particularly in tumors expressing a mesenchymal 
phenotype. First, what pathways are aberrantly regulated for tumor progression in mesenchymal 
tumors? Secondly, how do tumors experiencing limited nutrient and O2 levels upregulate pro-
survival factors? The models used to answer these questions were soft tissue sarcoma (Chapter 
2) and glioblastoma (Chapter 3). In chapter 2, I demonstrated that the Hippo pathway is 
aberrantly inhibited in multiple aggressive STS subtyptes, leading to elevated YAP and FOXM1 
activity. These factors, in turn, activate a potent pro-proliferation set of targets. Additionally, I 
demonstrated that YAP and FOXM1 may co-operate in the nucleus, and that pharmacologic 
inhibition of either YAP or FOXM1 can lead to decreased tumorigenesis. In chapter 3, I showed 
that miR-124 expression in glioblastoma cells experiencing hypoxia/ischemia results in increased 
cell death. I identified three key miR-124 targets which are upregulated under limited nutrients 
and O2. I verified that miR-124-mediated negative regulation of these targets (particularly of 
SERP1) is responsible for the cell death associated with miR-124 expression. Taken together, 
these studies add to our understanding of mesenchymal tumor progression. Here, I will attempt to 
address some of the implications that arise from these bodies of work. In addition, I will suggest 
several future directions to build on these stories.  
HIPPO PATHWAY IN SARCOMA 
The data presented in chapter II of this dissertation comprise one of the first attempts to 
define a role for Hippo pathway loss in high-grade sarcomas. Our work suggests that genetic 
aberrations in key upstream members of the Hippo pathway cause YAP overexpression and 
hyperproliferation. Moreover, we identify for the first time a functional interaction between 
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YAP/TEAD and another potent transcription factor, FOXM1. Mizuno and colleagues had 
previously identified FOXM1 as a direct YAP/TEAD target (Mizuno et al., 2012). Taken together, 
these findings suggest that YAP/TEAD/FOXM1 may cooperate as a complex that is also a 
positive feed-forward loop for FOXM1 regulation. However, these findings are preliminary and 
further work needs to biochemically address how FOXM1 interacts with the YAP/TEAD complex. 
We have shown that TEAD immunoprecipitates with FOXM1 but YAP does not. This was 
surprising, as YAP has been shown to directly interact with FOXO1, another forkhead 
transcription factor (Shao et al., 2014). It will be interesting to see how exactly TEAD and FOXM1 
bind, and whether this complex enhances TEAD/YAP association or weakens it. In addition, we 
took advantage of ENCODE data to delineate a few targets that may be co-transcribed from 
TEAD and FOXM1. However the data presented there is acquired from ChIP-seq analyses in 
different cell lines, under different conditions. In the future, it will be important to identify all the 
common and disparate FOXM1 and TEAD targets, in the context of sarcoma, but also in normal 
cells. It is possible, for example, that TEAD and FOXM1 cooperate towards the transcription of 
factors involved in cell cycle progression, but target completely different factors implicated in 
migration, invasion, or cell survival. Comparing a FOXM1 ChIP-seq analysis to a TEAD1 ChIP-
seq analysis from the same cells would allow us to elucidate that question. Moreover, it will be 
important to learn how TEAD1 and FOXM1 behave in the context of normal cells. Do they interact 
during normal development (e.g. in embryonic stem cells) or is this interaction specific to 
sarcoma? If the former is true, then FOXM1 can be considered a downstream effector of the 
Hippo pathway, and it will be important to evaluate how, if at all, FOXM1 is controlled by 
upstream Hippo pathway members. If the latter is the case, and the YAP/TEAD/FOXM1 complex 
is a property of tumors but not normal cells, then that finding would provide a powerful tool for 
novel targeted therapies. Regardless, the observation that YAP/TEAD/FOXM1 may interact in a 
complex needs to be followed up with more extensive experiments and should be a goal of future 
work.  
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Using an autochthonous model of sarcoma, we have shown that FOXM1 is a key target 
for sarcoma tumor progression, as FOXM1 deletion ablated tumor formation. Currently, we are 
addressing whether Yap ablation induces the same phenotype, by generating KrasG12D/+; Trp53fl/fl; 
Yapfl/fl animals. Based on the remaining in vitro and in vivo data presented in chapter II, I 
hypothesize that Yap deletion will result in ablated tumor formation as well. In addition, the 
availability of genetic models to dissect the Hippo pathway allows the field to further probe 
whether Yap is necessary for sarcoma formation. Similar to experiments performed by Tremblay 
and colleagues, wildtype Yap, or YAP S112A (mouse equivalent of S127) overexpressing mice 
crossed to LSL KrasG12D/+ or  Trp53fl/fl, or LSL KrasG12D/+; Trp53fl/fl can be queried to address those 
questions. Alternatively, Nf2, or Mst1/Mst2, or Sav1 deletion would address the same question, 
while at the same time mimic genetic changes in the Hippo pathway that are observed in 
sarcoma patients (Fig. 20).  
As mentioned in chapter II, our TCGA query of sarcoma patients yielded copy number 
variations for NF2, LATS2, and SAV1. We limited our analysis to the core kinase cassette players 
and a few upstream factors. However as discussed in chapter I, we consider many factors to be 
upstream of the core Hippo pathway (Fig. 1, Table 1). It would be interesting to evaluate every 
upstream member of the Hippo pathway for copy number variation and gene expression 
changes. In particular, Fat4 and Dchs1 PCP members (mammalian counterparts of Ft and Ds) 
are highly expressed in a variety of mesenchymal cells (Mao et al., 2011). It is possible that key 
members of apico-basal and planar cell polarity complexes are aberrantly regulated in sarcoma. 
However, one caveat of TCGA data is that, as of the time this document was written, sample 
banking and pathologic descriptions are still a work in progress. It was difficult for us to assess 
mRNA expression data from the currently accessible samples, as, while there were more than a 
hundred sarcoma samples for comparison, only two normal tissue samples were made available. 
In addition, almost half of the sarcoma samples present in the database were not defined by 
subgroup. Thus, it was not possible to compare mRNA expression data or CNV data between 
different sarcoma subtypes. These technical difficulties however are likely to dissipate in the near 
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future. It will be very interesting to query both CNV changes and mRNA expression levels for all 
key players of the Hippo pathway, and ask whether certain subtypes track with pathway 
perturbations. This could become crucial information, should clinical treatments against YAP 
become available in the near future.  
Another direction of future research will be to investigate other YAP/TEAD targets and 
their roles in sarcomagenesis. Calvo and colleagues demonstrated that YAP can act downstream 
of mechanotransduction signals to regulate the expression of ANLN and DIAPH3, two regulators 
of cytoskeleton function (Calvo et al., 2013). In this paper, the authors argue that activated YAP in 
Cancer-Associated Fibroblasts (CAFs) is necessary for CAF maintenance. Being mesenchymal 
in nature, sarcomas don’t necessarily have to rely on CAFs for tumor progression. In fact, we 
have previously shown that in our mouse models, more than 90% of the fibroblast-like cells 
originate from the primary tumor, and not the microenvironment, and suggested that sarcoma 
cells modify their microenvironment to promote metastatic progression in a cell autonomous 
manner. Although it will be challenging to dissect proliferation-related phenotypes form events 
promoting metastasis, it would be interesting to investigate the role of YAP (or of a downstream 
factor that does not display a proliferation phenotype when ablated) in sarcoma metastasis 
formation.  
Finally, as sarcomas are characterized by high levels of intratumoral hypoxia/ischemia, it 
will be interesting to evaluate how YAP expression and localization is affected by limited nutrients 
and O2.  Some of my preliminary data in fibroblasts has shown that YAP phosphorylation 
increases when cells are grown in limited O2 levels, and that eventually YAP levels diminish as 
cells are exposed to low O2 for periods longer than 24 hours. One hypothesis is that cells may 
restrict YAP function when experiencing a lack of nutrients and O2, similarly to the ways 
glioblastoma cells potentially engage in pro-survival stress response by elevating pro-survival 
SERP1 and diminishing miR-124 levels. Restricting YAP function could be beneficial in a 
pathologic setting such as tissue injury, before revascularization has allowed for replete 
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nutrient/O2 conditions, as proliferation under nutrient deprivation or hypoxia could lead to further 
cell death and tissue damage. In fact, some further evidence to support this hypothesis comes 
from a mouse testis model, where HIF2α deletion results in downregulation of tight junction 
proteins such as ZO1 and ZO2 . Since YAP may interact with ZO1 and ZO2 via its PDZ motif, it is 
possible that YAP could be sequestered away from the nucleus under hypoxia in a HIF-
dependent manner. However, YAP restriction at tight and adherens junctions as a method of 
inactivation is controversial, as further evidence has shown that YAP can freely shuttle from the 
adherens junction to the nucleus, at least in the context of YAP/Angiomotin interaction (Yi et al., 
2013). Thus, more work needs to be done to assess whether this is a viable hypothesis. 
Interestingly, hypoxia has been shown to affect cell shape, as hypoxic cells secrete and 
modify extracellular matrix components, possibly in order to create a “highway” for metastatic 
dissemination. In sarcoma, our lab has shown that HIF-1α - mediated PLOD2 expression results 
in collagen modifications that create a stiffer ECM (Eisinger-Mathason et al., 2013). Similar 
results have been described in other tumor models (Erler et al., 2006; Gilkes et al., 2013; Wong 
et al., 2011; Wong et al., 2012). Taken together with the evidence that mechanotransduction 
signaling resulting from changes in stiffness can affect YAP function (Dupont et al., 2011), it is 
possible that the Hippo and the Hypoxia inducible Factors cross-talk through cell stiffness 
changes. In fact, our preliminary observations from IHC experiments have shown that YAP 
expression is more nuclear and more intense at the migratory edge of tumors, as compared to 
more intratumoral regions. As upstream factors affecting the Hippo pathway remain incompletely 
understood, it would be interesting to query whether a crosstalk between the Hippo pathway and 
O2 sensing does in fact occur.  
MIR-124 AND GLIOBLASTOMA 
 In chapter III, I identify three novel miR-124 targets (MAPK14, TEAD1 and SERP1) and 
suggest that negative regulation of these targets by miR-124 causes cell death, specifically when 
glioblastoma cells are experiencing low nutrients and O2, the experimental equivalent to 
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intratumoral hypoxia and ischemia. Our work suggests that inhibiting these targets could be a 
way to target glioblastoma cells that survive in hypoxic/ischemic regions of the tumor, cells that 
have been difficult to target by our current treatment modalities. However, it would be more 
beneficial to identify a pathway, or a series of common factors that get differentially expressed 
under hypoxic/ischemic conditions. miR-124 could still serve as an interesting tool for identifying 
such factors, as we already know that miR-124 expression will induce cell death under stress, 
thereby affecting many factors important for survival. An RNA-seq analysis of the global targets 
differentially modulated by miR-124 ectopic expression in cells experiencing hypoxia, nutrient 
deprivation, or both, would be important towards the identification of pathways and key factors 
implicated in survival under stress conditions. Cells grown under hypoxia, nutrient deprivation, or 
a combination of both might lead to different top hits upon miR-124 modulation. Regardless, that 
information could be useful in identifying what factors are important for survival under nutrient 
deprivation vs. O2 deprivation. Equally important, factors that are upregulated under all the 
aforementioned conditions could be considered lynchpins in glioblastoma survival under 
ischemia. SERP1 might be such a factor, as we and others have now shown that it can be 
upregulated both under low O2, limiting nutrients/growth factors, and under ER stress (Hori et al., 
2006b; Mucaj et al., 2014; Yamaguchi et al., 1999b). Therefore, further studies on the mechanism 
by which SERP1 affects cell survival under stress are warranted.  
 As mentioned in chapter III, two different studies show evidence for SERP1 upregulation 
and miR-124 deregulation in mouse and rat models of ischemia (Liu et al., 2011; Yamaguchi et 
al., 1999b). It is tempting to speculate that miR-124 is downregulated in stroke regions so that 
pro-survival factors like SERP1 can become elevated. However, this needs to be experimentally 
tested. If that hypothesis is validated, then it would be intriguing to test whether one of the 
explanations for why there is increased neuronal cell death in stroke patients is that high miR-124 
levels in differentiated neurons is inhibiting the upregulation of factors like SERP1, TEAD1, p38α 
and other proteins necessary for adaptation under stress. However, ischemic induced neuronal 
96 
 
cell death is a multifaceted process that requires more sophisticated explanations outside of miR-
124 expression in neurons.  
 One caveat of the glioblastoma work described in chapter III is that in vivo experiments 
were performed in xenograft models, which, even when injected orthotopically, do not recapitulate 
the full microenvironment experienced by glioblastoma tumors. For example, while our models 
showed evidence for intratumoral hypoxia, they do not exhibit the same migratory and invasive 
phenotypes seen in patient glioblastoma tissues. In addition, they do not allow for the proper 
recruitment of the immune system. A 2011 paper described a role for miR-124 in inducing 
microglia quiescence in the brain (Ponomarev et al., 2011). As microglia comprise a large portion 
of glioblastoma mass (Charles et al., 2012), it is important to understand how miR-124 expression 
affects their function within the glioma tumor microenviroment. Additionally, by directly targeting 
STAT3, miR-124 can counteract T-cell mediated immunosuppression in a glioblastoma model. 
This would suggest that a potential miR-124 treatment could affect glioblastoma mass threefold. 
First, it could decrease tumor size by targeting factors such as CDK6 and TEAD1 and inhibiting 
proliferation. Secondly, it could target cells residing in hypoxic/ischemic regions by inhibiting 
SERP1 and MAPK14 expression. And lastly it could enhance T-cell mediated immune clearance 
(Wei et al., 2013). Performing this experiment however would require an efficient way of targeting 
miRNAs to the brain, which is currently a technical challenge. A genetic model crossing a 
glioblastoma tumor model (such as GFAP-Cre, NF1fl/fl; Trp53fl/fl mouse) to a mouse with 
conditional deletions of miR-124 would also be technically challenging, as there are three 
intergenic miR-124 loci in mammalian genomes (Visvader, 2011) (Clark et al., 2010). In fact, as of 
right now, the only miR-124 knockdown has been accomplished in C. elegans, as they possess 
only one copy of miR-124. In the future, it might be more feasible to deliver miR-124 mimics to 
analyze the role of ectopic expression of this miRNA in inhibiting glioblastoma progression.  
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